View Filing Data

Document and Entity Information - shares	9 Months Ended
Document and Entity Information - shares	Sep. 30, 2019	Oct. 28, 2019
Document and Entity Information [Abstract]
Entity Registrant Name	Chembio Diagnostics, Inc.
Entity Central Index Key	0001092662
Current Fiscal Year End Date	--12-31
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Shell Company	false
Entity Filer Category	Accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Common Stock, Shares Outstanding		17,565,534
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Sep. 30, 2019
Document Fiscal Year Focus	2019
Document Fiscal Period Focus	Q3
Entity Address, State or Province	NY

CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) - USD ($)	Sep. 30, 2019	Dec. 31, 2018
CURRENT ASSETS:
Cash and cash equivalents	$ 21,867,892	$ 12,524,551
Accounts receivable, net of allowance for doubtful accounts of $42,000 at September 30, 2019 and December 31, 2018	5,377,985	7,373,971
Inventories, net	8,409,344	7,851,222
Prepaid expenses and other current assets	598,127	702,010
TOTAL CURRENT ASSETS	36,253,348	28,451,754
FIXED ASSETS:
Property, plant and equipment, net	5,245,794	2,873,920
Finance lease right-of-use assets	222,036	0
FIXED ASSETS	5,467,830	2,873,920
OTHER ASSETS:
Operating lease right-of-use assets	6,697,896	0
Intangible assets, net	3,508,594	3,884,831
Goodwill	4,681,511	4,983,127
Deposits and other assets	308,159	717,551
OTHER ASSETS	15,196,160	9,585,509
TOTAL ASSETS	56,917,338	40,911,183
CURRENT LIABILITIES:
Accounts payable and accrued liabilities	5,445,956	5,888,681
Deferred revenue	237,500	422,905
Current portion of long-term debt	207,694	207,694
Current portion of finance lease liabilities	41,169	0
Current portion of operating lease liabilities	255,030	0
TOTAL CURRENT LIABILITIES	6,187,349	6,519,280
OTHER LIABILITIES:
Long-term operating lease liabilities	6,706,918	0
Long-term finance lease liabilities	182,702	0
Long-term debt, less current portion and debt discount and issuance costs	17,538,481	171,821
Deferred tax liability	505,618	892,308
TOTAL LIABILITIES	31,121,068	7,583,409
COMMITMENTS AND CONTINGENCIES
STOCKHOLDERS' EQUITY:
Preferred stock - 10,000,000 shares authorized; none outstanding	0	0
Common stock - $.01 par value; 100,000,000 shares authorized; 17,565,534 and 17,166,459 shares issued and outstanding at September 30, 2019 and December 31, 2018, respectively	175,655	171,664
Additional paid-in capital	93,376,856	90,953,788
Accumulated deficit	(67,696,092)	(57,909,874)
Accumulated other comprehensive (loss) income	(60,149)	112,196
TOTAL STOCKHOLDERS' EQUITY	25,796,270	33,327,774
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	$ 56,917,338	$ 40,911,183

CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical) - USD ($)	Sep. 30, 2019	Dec. 31, 2018
CURRENT ASSETS:
Accounts receivable, allowance for doubtful accounts	$ 42,000	$ 42,000
STOCKHOLDERS' EQUITY:
Preferred stock, shares authorized (in shares)	10,000,000	10,000,000
Preferred stock, shares outstanding (in shares)	0	0
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01
Common stock, shares authorized (in shares)	100,000,000	100,000,000
Common stock, shares issued (in shares)	17,565,534	17,166,459
Common stock, shares outstanding (in shares)	17,565,534	17,166,459

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
REVENUES:
TOTAL REVENUES	$ 9,720,939	$ 9,825,125	$ 27,613,291	$ 26,810,852
COSTS AND EXPENSES:
Cost of product sales	6,649,114	7,223,081	18,112,676	17,824,557
Research and development expenses	2,223,939	1,897,751	6,542,591	5,736,265
Selling, general and administrative expenses	4,455,588	3,034,130	12,565,601	7,987,914
Acquisition costs	0	0	395,612	0
TOTAL COSTS AND EXPENSES	13,328,641	12,154,962	37,616,480	31,548,736
LOSS FROM OPERATIONS	(3,607,702)	(2,329,837)	(10,003,189)	(4,737,884)
OTHER EXPENSE:
Interest (expense) income, net	(195,970)	15,656	(183,368)	42,985
LOSS BEFORE INCOME TAXES	(3,803,672)	(2,314,181)	(10,186,557)	(4,694,899)
Income tax benefit	20,667	0	400,339	0
NET LOSS	$ (3,783,005)	$ (2,314,181)	$ (9,786,218)	$ (4,694,899)
Basic loss per share (in dollars per share)	$ (0.22)	$ (0.16)	$ (0.58)	$ (0.34)
Diluted loss per share (in dollars per share)	$ (0.22)	$ (0.16)	$ (0.58)	$ (0.34)
Weighted average number of shares outstanding, basic (in shares)	16,923,695	14,173,620	16,912,583	13,872,055
Weighted average number of shares outstanding, diluted (in shares)	16,923,695	14,173,620	16,912,583	13,872,055
Net Product Sales [Member]
REVENUES:
TOTAL REVENUES	$ 8,510,629	$ 8,304,370	$ 23,381,906	$ 22,108,727
License and Royalty Revenue [Member]
REVENUES:
TOTAL REVENUES	238,330	228,553	703,352	707,010
Research and Development and Grant Revenue [Member]
REVENUES:
TOTAL REVENUES	$ 971,980	$ 1,292,202	$ 3,528,033	$ 3,995,115

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS (Unaudited) [Abstract]
Net loss	$ (3,783,005)	$ (2,314,181)	$ (9,786,218)	$ (4,694,899)
Other comprehensive loss:
Foreign currency translation adjustments	(61,306)	(104,657)	(172,345)	(26,187)
Comprehensive loss	$ (3,844,311)	$ (2,418,838)	$ (9,958,563)	$ (4,721,086)

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References + Details

CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (Unaudited) - USD ($)	Common Stock [Member]	Additional Paid-in-Capital [Member]	Accumulated Deficit [Member]	AOCI [Member]	Total
Balance at Dec. 31, 2017	$ 123,185	$ 62,821,288	$ (50,044,225)	$ 178,948	$ 13,079,196
Balance (in shares) at Dec. 31, 2017	12,318,570
Common Stock:
New stock from offerings	$ 17,838	10,916,514	0	0	10,934,352
New stock from offerings (in shares)	1,783,760
Options:
Exercised	$ 604	71,309	0	0	71,913
Exercised (in shares)	60,372
Stock option compensation	$ 0	97,250	0	0	97,250
Foreign currency translation adjustments	0	0	0	252,298	252,298
Net loss	0	0	(652,343)	0	(652,343)
Balance at Mar. 31, 2018	$ 141,627	73,906,361	(50,696,568)	431,246	23,782,666
Balance (in shares) at Mar. 31, 2018	14,162,702
Balance at Dec. 31, 2017	$ 123,185	62,821,288	(50,044,225)	178,948	13,079,196
Balance (in shares) at Dec. 31, 2017	12,318,570
Options:
Foreign currency translation adjustments					(26,187)
Net loss					(4,694,899)
Balance at Sep. 30, 2018	$ 141,736	74,108,046	(54,739,124)	152,761	19,663,419
Balance (in shares) at Sep. 30, 2018	14,173,620
Balance at Mar. 31, 2018	$ 141,627	73,906,361	(50,696,568)	431,246	23,782,666
Balance (in shares) at Mar. 31, 2018	14,162,702
Options:
Exercised	$ 109	(109)	0	0	0
Exercised (in shares)	10,918
Stock option compensation	$ 0	127,035	0	0	127,035
Foreign currency translation adjustments	0	0	0	(173,828)	(173,828)
Net loss	0	0	(1,728,375)	0	(1,728,375)
Balance at Jun. 30, 2018	$ 141,736	74,033,287	(52,424,943)	257,418	22,007,498
Balance (in shares) at Jun. 30, 2018	14,173,620
Options:
Exercised	$ 0	0	0	0	0
Exercised (in shares)	0
Stock option compensation	$ 0	74,759	0	0	74,759
Foreign currency translation adjustments	0	0	0	(104,657)	(104,657)
Net loss	0	0	(2,314,181)	0	(2,314,181)
Balance at Sep. 30, 2018	$ 141,736	74,108,046	(54,739,124)	152,761	19,663,419
Balance (in shares) at Sep. 30, 2018	14,173,620
Balance at Dec. 31, 2018	$ 171,664	90,953,788	(57,909,874)	112,196	33,327,774
Balance (in shares) at Dec. 31, 2018	17,166,459
Common Stock:
Restricted stock compensation	$ 0	281,248	0	0	281,248
Options:
Stock option compensation	0	66,259	0	0	66,259
Foreign currency translation adjustments	0	0	0	202,186	202,186
Net loss	0	0	(2,816,533)	0	(2,816,533)
Balance at Mar. 31, 2019	$ 171,664	91,301,295	(60,726,407)	314,382	31,060,934
Balance (in shares) at Mar. 31, 2019	17,166,459
Balance at Dec. 31, 2018	$ 171,664	90,953,788	(57,909,874)	112,196	33,327,774
Balance (in shares) at Dec. 31, 2018	17,166,459
Options:
Foreign currency translation adjustments					(172,345)
Net loss					(9,786,218)
Balance at Sep. 30, 2019	$ 175,655	93,376,856	(67,696,092)	(60,149)	25,796,270
Balance (in shares) at Sep. 30, 2019	17,565,534
Balance at Mar. 31, 2019	$ 171,664	91,301,295	(60,726,407)	314,382	31,060,934
Balance (in shares) at Mar. 31, 2019	17,166,459
Common Stock:
Restricted stock issued	$ 3,750	(3,750)	0	0	0
Restricted stock issued (in shares)	375,000
Restricted stock compensation	$ 0	307,774	0	0	307,774
Options:
Exercised	$ 241	(241)	0	0	0
Exercised (in shares)	24,075
Stock option compensation	$ 0	69,097	0	0	69,097
Foreign currency translation adjustments	0	0	0	(313,225)	(313,225)
Net loss	0	0	(3,186,680)	0	(3,186,680)
Balance at Jun. 30, 2019	$ 175,655	91,674,175	(63,913,087)	1,157	27,937,900
Balance (in shares) at Jun. 30, 2019	17,565,534
Common Stock:
Restricted stock compensation	$ 0	440,396	0	0	440,396
Options:
Stock option compensation	0	66,192	0	0	66,192
Warrant on term debt	0	1,196,093	0	0	1,196,093
Foreign currency translation adjustments	0	0	0	(61,306)	(61,306)
Net loss	0	0	(3,783,005)	0	(3,783,005)
Balance at Sep. 30, 2019	$ 175,655	$ 93,376,856	$ (67,696,092)	$ (60,149)	$ 25,796,270
Balance (in shares) at Sep. 30, 2019	17,565,534

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) - USD ($)	3 Months Ended				6 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2019	Mar. 31, 2019	Sep. 30, 2018	Mar. 31, 2018	Jun. 30, 2019	Jun. 30, 2018	Sep. 30, 2019	Sep. 30, 2018	Dec. 31, 2018	Dec. 31, 2017
CASH FLOWS FROM OPERATING ACTIVITIES:
Cash received from customers and grants		$ 8,110,466		$ 6,347,198	$ 18,165,872	$ 12,795,497	$ 29,423,872	$ 21,812,928	$ 29,804,273	$ 26,164,823
Cash paid to suppliers and employees		(12,590,425)		(8,666,444)	(24,959,732)	(17,900,495)	(35,185,776)	(29,386,421)	(41,624,299)	(31,221,823)
Cash paid for operating leases	$ (158,050)						(474,150)	0
Cash paid for finance leases	(4,033)						(4,033)	0
Interest and taxes, net							(158,120)	42,985
Net cash used in operating activities							(6,398,207)	(7,530,508)
CASH FLOWS FROM INVESTING ACTIVITIES:
Patent application costs							(346,663)	0
Acquisition of and deposits on fixed assets							(2,568,244)	(401,897)
Working capital adjustment related to business combination							145,760	0
Net cash used in investing activities							(2,769,147)	(401,897)
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from option exercises							0	71,914
Proceeds from issuance of long-term debt, net							18,850,000	0
Payments on debt issuance costs							(186,313)	0
Payments on note payable							(136,232)	(15,800)
Proceeds from sale of common stock, net							0	10,934,352
Principal payments for finance leases	(9,851)						(9,851)	0
Net cash provided by financing activities							18,517,604	10,990,466
Effect of exchange rate changes on cash							(6,909)	220
INCREASE IN CASH AND CASH EQUIVALENTS							9,343,341	3,058,281
Cash and cash equivalents - beginning of the period		12,524,551		3,790,302	$ 12,524,551	$ 3,790,302	12,524,551	3,790,302	3,790,302
Cash and cash equivalents - end of the period	21,867,892		6,848,583				21,867,892	6,848,583	$ 12,524,551	$ 3,790,302
RECONCILIATION OF NET LOSS TO NET CASH USED IN OPERATING ACTIVITIES:
Net loss	$ (3,783,005)	$ (2,816,533)	$ (2,314,181)	$ (652,343)			(9,786,218)	(4,694,899)
Adjustments:
Depreciation and amortization							1,666,675	663,250
Share based compensation							1,230,966	299,044
Benefit from deferred tax liability							(402,639)	0
Changes in assets and liabilities:
Accounts receivable							1,995,986	(5,708,674)
Inventories							(558,122)	(1,554,808)
Prepaid expenses and other current assets							103,883	(997,468)
Deposits and other assets							(20,608)	0
Accounts payable and accrued liabilities							(442,725)	3,752,297
Deferred revenue							(185,405)	710,750
Net cash used in operating activities							(6,398,207)	(7,530,508)
Supplemental disclosures for non-cash investing and financing activities:
Deposits on manufacturing equipment transferred to fixed assets							430,000	268,655
Seller-financed equipment purchases							$ 0	$ 326,110

DESCRIPTION OF BUSINESS	9 Months Ended
DESCRIPTION OF BUSINESS	Sep. 30, 2019
DESCRIPTION OF BUSINESS [Abstract]
DESCRIPTION OF BUSINESS	NOTE 1 — DESCRIPTION OF BUSINESS: Chembio Diagnostics, Inc. and its subsidiaries (collectively, the “Company” or “Chembio”) develop, manufacture, and commercialize point-of-care (“POC”) diagnostic tests that are used to detect or monitor diseases. The Company’s product development efforts are focused on its patented DPP technology, a novel POC diagnostic platform that offers certain customer advantages as compared to traditional lateral flow technology. POC tests, by providing prompt and early diagnosis, can reduce patient stays, lower overall costs, improve therapeutic interventions, and improve patient outcomes. POC tests can also prevent needless hospital admissions, simplify testing procedures, avoid delays from central lab batching, and eliminate the need for return visits. The Company’s product commercialization and product development efforts are focused in two areas: infectious disease, which includes both sexually transmitted and tropical and fever disease; and strategic collaborations with leading global healthcare companies, which leverage the DPP platform to provide Chembio with additional revenue streams. In infectious disease, the Company is commercializing tests for HIV, Syphilis, Zika virus, dengue virus, chikungunya virus, and ebola, and developing tests for malaria, lassa, Marburg, leptospirosis, Rickettsia typhi, Burkholderia pseudomallei, and Orientia tsutsugamushi. Certain of these are being developed as part of fever panel tests. Through strategic collaborations, the Company is developing tests for a specific form of cancer, concussions, bovine tuberculosis, and for eosinophilic respiratory disease the last in collaboration with global pharmaceutical company AstraZeneca. Chembio is also developing a point-of-care test for an undisclosed biomarker for Takeda, also a global pharmaceutical company. Large and growing markets have been established for these kinds of tests, initially in high prevalence regions where they are critical for large scale prevention and treatment programs. The Company’s product development is focused on areas where the availability of rapid, POC screening, diagnostic, or confirmatory results can improve health outcomes. More generally, the Company believes there is and will continue to be a growing demand for diagnostic products that can provide accurate, actionable diagnostic information in a rapid, cost-effective manner at the point of care. The Company’s products are sold to medical laboratories and hospitals, governmental and public health entities, non-governmental organizations, medical professionals and retail establishments, both domestically and internationally, under its STAT-PAK, SURE CHECK, STAT-VIEW and DPP registered trademarks, or under the private labels of its marketing partners. The Company routinely enters into arrangements with governmental and non-governmental organizations for the funding of certain research and development (“R&D”) efforts.

ACQUISITION

9 Months Ended

Sep. 30, 2019

ACQUISITION [Abstract]

ACQUISITION

NOTE 2 — ACQUISITION:

On November 6, 2018, pursuant to a share purchase agreement, the Company acquired all of the outstanding shares of opTricon GmbH (subsequently renamed Chembio Diagnostics GmbH), a privately held German developer and manufacturer of handheld analyzers for rapid diagnostic tests, for $5.5 million in cash. Since 2015, the two parties collaborated in developing theDPP Micro Reader, a handheld, battery-operated analyzer that uses an innovative image sensor to provide, when combined with the Company’s DPP tests, a quantitative interpretation of diagnostic results. The Company believes the acquisition will enable it to promote DPP tests and DPP Micro Readers more actively across global markets. The results of the acquired company’s operations have been reflected in the consolidated financial statements since November 6, 2018.

As a result of the consideration paid exceeding the fair value of the net assets acquired, goodwill in the amount of $3,337,000 was recorded in connection with this acquisition, none of which will be deductible for tax purposes. In addition, the Company recorded $2,260,000 in intangible assets associated with the addition of developed technology and customer base from the acquisition. During the nine months ended September 30, 2019, the Company reduced goodwill by $145,760 related to routine post-closing adjustments. The consolidated statements of operations for the three and nine months ended September 30, 2019 include $0 and $395,612 of transaction costs related to the acquisition.

The acquisition was accounted for using the purchase method of accounting. The following table summarizes the preliminary allocation of the purchase price to the estimated fair values of the assets acquired and liabilities assumed on the closing date of November 6, 2018:

	Amount
Net current assets	$	404,204
Property, plant and equipment		125,000
Goodwill		3,337,000
Deferred tax liability		(635,000	)
Other intangible assets (estimated useful life):
Developed technology (7 years)		1,900,000
Customer contracts / relationships (10 years)		360,000
Total consideration	$	5,491,204

The Company calculated the fair value of the fixed assets based on the net book value of the acquired company, as net book value approximated fair value. The developed technology and customer contracts and relationships were based on discounted cash flows using management estimates.

As indicated, the allocation of the purchase price shown above is preliminary, pending completion of an analysis of the deferred tax liability. Therefore, an adjustment may be required.

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

9 Months Ended

Sep. 30, 2019

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES [Abstract]

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

NOTE 3 — SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES:

Basis of Presentation:

The preceding (a) condensed consolidated balance sheet as of December 31, 2018, which has been derived from audited financial statements, and (b) unaudited interim condensed consolidated financial statements as of September 30, 2019 and for the three and nine months ended September 30, 2019 and 2018 have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”). Certain information and footnote disclosures, which are normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States, have been condensed or omitted pursuant to such rules and regulations. In the opinion of management, all adjustments (which include normal recurring adjustments) necessary to present a fair statement of the Company’s condensed consolidated financial position as of September 30, 2019 and its condensed consolidated results of operations for the three and nine months ended September 30, 2019 and 2018 have been made. The interim financial information should be read in conjunction with the financial statements and the notes thereto included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2018, which was filed with the SEC on March 18, 2019. The interim results of operations are not necessarily indicative of the operating results for the full fiscal year or any future periods.

The Company’s future working capital needs will depend on many factors, including the rate of its business and revenue growth, the timing of its continuing automation of U.S. manufacturing, and the timing of its investment in R&D as well as sales and marketing. The Company believes that its existing cash and cash equivalents will be sufficient to meet the Company’s anticipated cash needs for the foreseeable future consistent with its long-term operating plan. If, however, this source of liquidity becomes insufficient to fund the growth of the Company’s business, the Company may need to reduce the level or slow the timing of its growth plans, which would likely curtail or delay the growth in the Company’s business contemplated by its operating plan and could impair or defer its ability to achieve profitability and generate cash flow, or to seek to raise additional funds through debt or equity financings, strategic relationships, or other arrangements.

In the opinion of management, all adjustments (which include normal recurring adjustments) necessary to present a fair statement of the Company’s condensed consolidated financial position as of September 30, 2019 and, its condensed consolidated results of operations for the three and nine months ended September 30, 2019 and 2018 have been made. (Note 3q - Error Correction) The interim results of operations are not necessarily indicative of the operating results for the full fiscal year or any future periods.

Revenue Recognition:

In May 2014, the Financial Accounting Standards Board (“FASB”) issued converged guidance on recognizing revenue in contracts with customers, Accounting Standards Update (“ASU”) No. 2014-09, Revenue from Contracts with Customers(Topic 606). The intent of the new standard is to improve financial reporting and comparability of revenue globally. The core principle of the standard is for a company to recognize revenue in a manner that depicts the transfer of goods or services to customers in an amount that reflects the consideration which the company expects to receive in exchange for those goods or services. The guidance provides a five-step analysis of transactions to determine when and how revenue is recognized. Other major provisions include capitalization of certain contract costs, consideration of the time value of money in the transaction price, and in certain circumstances, allowing estimates of variable consideration to be recognized before contingencies are resolved. The guidance also requires enhanced disclosures regarding the nature, amount, timing and uncertainty of revenue and cash flows arising from an entity’s contracts with customers.

The new revenue standards became effective for the Company on January 1, 2018 and were adopted using the modified retrospective method. The adoption of the new revenue standards as of January 1, 2018 did not change the Company’s revenue recognition as its revenues continue to be recognized when the customer takes control of its product. As the Company did not identify any material accounting changes that impacted the amount of reported revenues with respect to its product revenue, license and royalty revenue, and R&D and grant revenues, no adjustment to retained earnings was required upon adoption.

The Company adopted the standards for contracts that were not completed at the date of initial application (January 1, 2018).

Under the new revenue standards, the Company recognizes revenues when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the Company expects to receive in exchange for those goods or services. The Company recognizes revenues following the five-step model prescribed under ASU No. 2014-09: (i) identify contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenues when (or as) the Company satisfies the performance obligations.

Product Revenues

Revenues from product sales are recognized and commissions are accrued when the customer obtains control of the Company’s product, which occurs at a point in time, typically upon tendering to the customer. The Company expenses incremental costs of obtaining a contract as and when incurred because the expected amortization period of the asset that it would have recognized is one year or less or the amount is immaterial. Freight and distribution activities on products are performed after the customer obtains control of the goods. The Company has made an accounting policy election to account for shipping and handling activities that occur either when or after goods are tendered to the customer as a fulfillment activity, and therefore recognizes freight and distribution expenses in cost of product sales.

The Company’s payment terms vary by the type and location of the Company’s customer and products or services offered. Payment terms differ by jurisdiction and customer, but payment is generally required in a term ranging from 30 to 60 days from date of shipment or satisfaction of the performance obligation.

Reserves for Discounts and Allowances

Revenues from product sales are recorded net of reserves established for applicable discounts and allowances that are offered within contracts with the Company’s customers. The Company’s process for estimating reserves established for these variable consideration components does not differ materially from its historical practices.

Product revenue reserves, which are classified as a reduction in product revenues, are generally related to discounts. Estimates of variable consideration and the determination of whether to include estimated amounts in the transaction price are based on all information (historical, current and forecasted) that is reasonably available to the Company, taking into consideration the type of customer, the type of transaction and the specific facts and circumstances of each arrangement. The transaction price, which includes variable consideration reflecting the impact of discounts and allowances, may be subject to constraint and is included in the net sales price only to the extent that it is probable that a significant reversal of the amount of the cumulative revenues recognized will not occur in a future period. Actual amounts may ultimately differ from the Company’s estimates. If actual results vary, the Company adjusts these estimates, which could have an effect on earnings in the period of adjustment.

Royalty Revenues

The Company receives royalty revenues on sales by a licensee of products covered under patents that it owns. The Company does not have future performance obligations under this license arrangement. The Company records these revenues based on estimates of the sales that occurred during the relevant period as a component of license and royalty revenues. The relevant period estimates of sales are based on interim data provided by licensees and analysis of historical royalties that have been paid to the Company, adjusted for any changes in facts and circumstances, as appropriate. Differences between actual and estimated royalty revenues are adjusted for in the period in which they become known, typically the following quarter. Historically, adjustments have not been material when compared to actual amounts paid by licensees.

R&D and Grant Revenue

All R&D and grant contracts are evaluated under the five-step model described above. For certain contracts that represent grants where the funder does not meet the definition of a customer, the Company recognizes revenue when earned in accordance with ASU No. 2018-08, Not-for-Profit Entities (Topic 958): Clarifying the Scope and Accounting Guidance for Contributions Received and Contributions Made. Such contracts are further described under Disaggregation of Revenue, below. Grants are invoiced and revenue is recognized as expenses are incurred, as that is the depiction of the timing of the transfer of services. Performance obligations generally follow the major phases of product development processes: design feasibility and planning, product development and design optimization, design verification, design validation and process validation, and pivotal studies.

Disaggregation of Revenue

The following tables disaggregate total revenues:

	For the three months ended September 30, 2019						For the three months ended September 30, 2018
	Exchange Transactions		Non-Exchange Transactions		Total		Exchange Transactions		Non-Exchange Transactions		Total
Net product sales	$	8,510,629	$	-	$	8,510,629	$	8,304,370	$	-	$	8,304,370
License and royalty revenue		238,330		-		238,330		228,553		-		228,553
R&D and grant revenue		880,458		91,522		971,980		960,332		331,870		1,292,202
	$	9,629,417	$	91,522	$	9,720,939	$	9,493,255	$	331,870	$	9,825,125

					Total						Total
Africa					$	1,250,063					$	3,193,098
Asia						505,379						216,527
Europe & Middle East						1,629,965						1,666,066
Latin America						4,296,903						3,404,623
United States						2,038,629						1,344,811
					$	9,720,939					$	9,825,125

	For the nine months ended September 30, 2019						For the nine months ended September 30, 2018
	Exchange Transactions		Non-Exchange Transactions		Total		Exchange Transactions		Non-Exchange Transactions		Total
Net product sales	$	23,381,906	$	-	$	23,381,906	$	22,108,727	$	-	$	22,108,727
License and royalty revenue		703,352		-		703,352		707,010		-		707,010
R&D and grant revenue		2,272,454		1,255,579		3,528,033		2,328,058		1,667,057		3,995,115
	$	26,357,712	$	1,255,579	$	27,613,291	$	25,143,795	$	1,667,057	$	26,810,852

					Total						Total
Africa					$	6,009,103					$	7,156,822
Asia						746,025						1,212,839
Europe & Middle East						4,880,744						3,831,580
Latin America						9,981,874						9,743,764
United States						5,995,545						4,865,847
					$	27,613,291					$	26,810,852

Exchange transactions are recognized in accordance with ASU No. 2014-09, and non-exchange transactions are recognized in accordance with ASU No. 2018-08.

Contract Liabilities

Deferred revenue relates to payments received in advance of performance under the contract. Deferred revenue is recognized as revenue as (or when) the Company performs under the contract. At December 31, 2018, the Company reported $422,905 in deferred revenue, all of which was earned and recognized as R&D and grant revenue during the nine months ended September 30, 2019. At September 30, 2019, the Company reported $237,500 in deferred revenue that is expected to be recognized during the last quarter of 2019.

Inventories

Inventories consist of the following at:

	September 30, 2019		December 31, 2018
Raw materials	$	2,653,368	$	2,803,677
Work in process		1,313,045		263,043
Finished goods		4,442,931		4,784,502
	$	8,409,344	$	7,851,222

Inventories, consisting of material, labor and manufacturing overhead, are stated at the lower of cost and net realizable value. Cost is determined on the first-in, first-out method. The Company’s policy is to periodically evaluate the market value of the inventory and the stage of product life cycle, and record a write-down for any inventory considered slow moving or obsolete. There were reserves against inventory of approximately $67,000 and $78,000 as of September 30, 2019 and December 31, 2018, respectively.

Loss Per Share:

Basic loss per share is computed by dividing net loss attributable to common stockholders by the weighted-average number of common shares outstanding for the period excluding unvested restricted stock. Diluted loss per share for the three and nine months ended September 30, 2019 and 2018 reflects the potential dilution from the exercise or conversion of other securities into common stock, if dilutive.

There were 650,093 and 693,116 weighted-average number of options outstanding as of September 30, 2019 and 2018, respectively, that were not included in the calculation of diluted per common share equivalents for the three months ended September 30, 2019 and 2018, respectively, because the effect would have been anti-dilutive. There were 672,472 and 709,042 weighted-average number of options outstanding as of September 30, 2019 and 2018, respectively, that were not included in the calculation of diluted per common share equivalent for the nine months ended September 30, 2019 and 2018, respectively, because the effect would have been anti-dilutive. There were 550,000 shares of warrants issued in September 2019. The weighted average of these shares were excluded from the calculation of diluted EPS as the effect would have been anti-dilutive.

Stock Incentive Plan:

Effective June 3, 2008, the Company’s stockholders voted to approve the 2008 Stock Incentive Plan (the “2008 Plan”), with 625,000 shares of common stock available to be issued. At the Annual Stockholder Meeting on September 22, 2011 the Company’s stockholders voted to approve an increase to the shares of common stock issuable under the 2008 Plan by 125,000 to 750,000. Under the terms of the 2008 Plan, which expired during 2018, the Board of Directors (the “Board”) or its Compensation Committee had the discretion to select the persons to whom awards were to be granted. Awards could be stock options, restricted stock and/or restricted stock units (“Equity Award Units”). The Equity Award Units became vested at such times and under such conditions as determined by the Board or its Compensation Committee. Cumulatively through September 30, 2019, there were 508,889 options exercised, and at September 30, 2019, 99,132 options were outstanding and no Equity Award Units were available to be issued under the 2008 Plan.

Effective June 19, 2014, the Company’s stockholders voted to approve the 2014 Stock Incentive Plan (the “2014 Plan”), with 800,000 shares of common stock available to be issued. Under the terms of the 2014 Plan, the Board or its Compensation Committee has the discretion to select the persons to whom Equity Award Units were to be granted. Awards can be in the form of Equity Award Units. The Equity Award Units vest at such times and under such conditions as determined by the Board or its Compensation Committee. Cumulatively through September 30, 2019, there were 132,282 options exercised, and at September 30, 2019, 344,093 options were outstanding. Upon approval of the 2019 Plan (defined below), no additional Equity Award Units could be issued under the 2014 Plan. During 2018, 266,839 shares of restricted stock and 20,725 restricted stock units were awarded under the 2014 Plan.

Effective June 18, 2019, the Company’s stockholders voted to approve the 2019 Omnibus Incentive Plan (the “2019 Plan”), with 2,400,000 shares of common stock available to be issued. Under the terms of the 2019 Plan, the Board or its Compensation Committee has the discretion to select the persons to whom awards are to be granted. Awards can be in the form of Equity Award Units. The awards vest at such times and under such conditions as determined by the Board or its Compensation Committee. As of September 30, 2019, 375,000 shares of restricted stock had been awarded under the 2019 Plan, and 2,025,000 Equity Award Units were available to be issued.

Stock-Based Compensation:

The fair value of restricted stock and restricted stock unit awards are their fair value on the date of grant. Stock-based compensation expense for stock options is calculated using the Black-Scholes valuation model based on awards ultimately expected to vest, together with the fair value of restricted stock and restricted stock unit awards, are reduced for actual forfeitures and expensed on a straight-line basis over the requisite service period of the grant.

Stock option compensation expense in each of the periods presented represents the estimated fair value of unvested, outstanding options, amortized on a straight-line basis over the requisite vesting periods of the entire awards.

Stock-based compensation expense recognized in the condensed consolidated statements of operations was classified as follows:

	For the three months ended				For the nine months ended
	September 30, 2019		September 30, 2018		September 30, 2019		September 30, 2018
Cost of product sales	$	2,691	$	5,800	$	8,479	$	19,800
Research and development expenses		56,251		3,600		172,346		19,000
Selling, general and administrative expenses		447,646		65,359		1,050,141		260,244
	$	506,588	$	74,759	$	1,230,966	$	299,044

The weighted-average assumptions made in calculating the fair values of options are as follows:

	For the three months ended						For the nine months ended
	September 30, 2019			September 30, 2018			September 30, 2019			September 30, 2018
Expected term (in years)		N/A			4.5			N/A			4.9
Expected volatility		N/A	%		39.69	%		N/A	%		39.91	%
Expected dividend yield		N/A	%		0	%		N/A	%		0	%
Risk-free interest rate		N/A	%		2.70	%		N/A	%		2.70	%

The following table provides stock option activity for the nine months ended September 30, 2019:

Stock Options	Number of Shares		Weighted Average Exercise Price per Share		Weighted Average Remaining Contract Term	Aggregate Intrinsic Value
Outstanding at December 31, 2018		711,968	$	5.62	3.33 years	$	687,364

Granted		-		-			-
Exercised		46,875		3.48			172,242
Forfeited/expired/cancelled		15,000		5.68			30,286
Outstanding at September 30, 2019		650,093	$	5.77	2.79 years	$	730,142
Exercisable at September 30, 2019		447,759	$	4.98	2.16 years	$	713,762

The following table summarizes information about stock options outstanding at September 30, 2019:

	Stock Options Outstanding								Stock Options Exercisable
Range of Exercise Prices	Number of Shares		Average Remaining Contract Term (Year)		Weighted Average Exercise Price		Aggregate Intrinsic Value		Number of Shares		Weighted Average Exercise Price		Aggregate Intrinsic Value
1 to 2.79999		-		-	$	-	$	-		-	$	-	$	-
2.8 to 4.59999		257,468		1.41		3.44		689,143		257,468		3.44		689,143
4.6 to 6.39999		137,875		2.70		5.87		40,999		87,125		5.89		24,619
6.4 to 8.19999		207,875		4.31		7.31		-		84,416		7.32		-
8.2 to 12		46,875		3.85		11.45		-		18,750		11.45		-
Total		650,093		2.79	$	5.77	$	730,142		447,759	$	4.98	$	713,762

As of September 30, 2019, there was $496,296 of net unrecognized compensation cost related to stock options that had not vested, which is expected to be recognized over a weighted average period of approximately 1.82 years. The total fair value of shares vested during the nine months ended September 30, 2019 and 2018 was $295,412 and $379,384, respectively.

The following table summarizes information about restricted stock and restricted stock units outstanding as of September 30, 2019:

	Number of Shares & Units		Weighted Average Grant Date Fair Value
Outstanding at December 31, 2018		287,564	$	9.65

Granted		375,000		5.80
Earned/released		-		-
Forfeited/expired/cancelled		-		-
Outstanding at September 30, 2019		662,564	$	7.47

As of September 30, 2019, there was $3,639,325 of net unrecognized compensation cost related to restricted stock and restricted stock units that had not vested, which is expected to be recognized over a weighted average period of approximately 2.42 years.

Geographic Information and Economic Dependency

The Company produces only one group of similar products known collectively as “rapid medical tests”, and it operates in a single business segment. Net product sales by geographic area were as follows:

	For the three months ended				For the nine months ended
	September 30, 2019		September 30, 2018		September 30, 2019		September 30, 2018
Africa	$	1,250,063	$	3,193,098	$	6,009,103	$	7,156,822
Asia		505,379		216,527		746,025		1,212,839
Europe & Middle East		1,027,147		728,073		2,946,813		1,773,872
Latin America		4,296,904		3,404,683		9,981,874		9,743,764
United States		1,431,136		761,989		3,698,091		2,221,430
	$	8,510,629	$	8,304,370	$	23,381,906	$	22,108,727

Long-lived assets by geographic area were as follows at:

	September 30, 2019		December 31, 2018
Asia		419,719		466,185
Europe & Middle East		157,257		123,752
United States		4,668,818		2,283,983
	$	5,245,794	$	2,873,920

Fair Value of Financial Instruments:

Fair value measurements of all financial assets and liabilities that are being measured and reported on a fair value basis are required to be classified and disclosed in one of the following three categories:

Level 1:

Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities;

Level 2:

Quoted prices in markets that are not active, or inputs which are observable, either directly or indirectly, for substantially the full term of the asset or liability; and,

Level 3:

Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (i.e., supported by little or no market activity).

The carrying values for cash and cash equivalents, accounts receivable, accounts payable and accrued expenses and other current liabilities approximate fair value due to the immediate or short-term maturity of these financial instruments. Included in cash and cash equivalents were $20.5 million and $4.7 million as of September 30, 2019 and December 31, 2018, respectively, of money market funds that are Level 1 fair value measurements under the hierarchy.

The fair value of the Company’s total debt of $20.2 million (carrying value of $17.7 million) and $0.2 million as of September 30, 2019 and December 31, 2018, respectively, is a Level 2 fair value measurement under the hierarchy and the company’s debt face value approximates the recorded value as the rate is based upon the current rates available to the Company for similar financial instruments.

Accounts Payable and Accrued Liabilities:

Accounts payable and accrued liabilities consisted of:

	September 30, 2019		December 31, 2018
Accounts payable – suppliers	$	2,975,913	$	3,622,765
Accrued commissions and royalties		819,405		867,344
Accrued payroll		320,266		48,867
Accrued vacation		659,358		264,789
Accrued bonuses		497,190		494,318
Accrued expenses – other		173,824		590,598
TOTAL	$	5,445,956	$	5,888,681

Goodwill Long-Lived Assets and Intangible Assets:

Goodwill represents the excess of the purchase price the Company paid over the fair value of the net tangible and identifiable intangible assets acquired in the Company’s acquisition of Chembio Diagnostics GmbH in November 2018 and Chembio Diagnostics Malaysia Sdn Bhd in January 2017. Goodwill is not amortized but rather is tested annually as of the first day of the fiscal fourth quarter for impairment or more frequently if the Company believes that indicators of impairment exist. The Company makes a qualitative evaluation about the likelihood of goodwill impairment, which is based on a number of applicable factors. If the Company concludes that it is more likely than not that the carrying value of the applicable reporting unit is greater than its fair value, then the Company recognizes an impairment charge for the amount by which the carrying value exceeds the reporting unit’s fair value, provided the impairment charge does not exceed the total amount of goodwill allocated to the reporting unit.

The following table reflects changes in goodwill:

Beginning balance at December 31, 2018	$	4,983,127
Chembio Diagnostics GmbH measurement period adjustment		(145,760	)
Change in foreign currency exchange rate		(155,856	)
Balance at September 30, 2019	$	4,681,511

Intangible assets consisted of the following at:

	September 30, 2019							December 31, 2018
	Weighted Average Remaining Useful Life	Cost		Accumulated Amortization		Net Book Value		Cost		Accumulated Amortization		Net Book Value
Intellectual property	6	$	1,203,121	$	258,045	$	945,076	$	1,089,688	$	173,633	$	916,055
Developed technology	6		1,816,190		194,592		1,621,598		1,910,315		-		1,910,315
Customer contracts/relationships	8		1,093,521		231,894		861,627		1,121,600		151,929		969,671
Trade names	8		107,057		26,764		80,293		108,521		19,731		88,790
		$	4,219,889	$	711,295	$	3,508,594	$	4,230,124	$	345,293	$	3,884,831

Intellectual property, developed technology, customer contracts/relationships, and trade names are amortized over 10, 7, 10, and 11 years, respectively. Amortization expense for the nine months ended September 30, 2019 and 2018 was approximately $378,691 and $134,208, respectively. Amortization expense, subject to changes in currency exchange rates, is expected to be $499,871 per year from 2019 through 2023, and total $1,381,699 for all of the years thereafter.

Long-lived assets to be held and used are analyzed for impairment whenever events or changes in circumstances indicate that the related carrying amounts may not be recoverable. The Company evaluates at each balance sheet date whether events and circumstances have occurred that indicate possible impairment. If there are indications of impairment, the Company uses future undiscounted cash flows of the related asset or asset grouping over the remaining life in measuring whether the assets are recoverable. In the event such cash flows are not expected to be sufficient to recover the recorded asset values, the assets are written down to their estimated fair value.

No impairment of goodwill, long-lived tangible, and intangible assets was recorded for the nine months ended September 30, 2019 and 2018.

Taxes:

At the end of each interim reporting period, the Company estimates its effective tax rate expected to be applied for the full year. This estimate is used to determine the income tax provision or benefit on a year-to-date basis, and may change in subsequent interim periods. Accordingly, the Company’s effective tax benefit for the three and nine-month periods ended September 30, 2019 was 0.5% and 3.9%, compared to the effective tax rate of 0.0% for the three and nine-month periods ended September 30, 2018. The Company’s effective tax rates for both periods were affected primarily by a full valuation allowance on domestic net deferred tax assets and the benefit from foreign net operating losses.

R&D:

R&D costs are expensed as incurred. Advance payments for goods and services that will be used in future R&D activities are expensed when the activity has been performed or when the goods have been received rather than when the payment is made.

Allowance for Doubtful Accounts:

The Company records allowances for doubtful accounts for the estimated probable losses on uncollectible accounts receivable. The allowance is based upon the credit worthiness of the Company’s customers, the Company’s historical experience, the age of the receivable and current market and economic conditions. Receivables are written off against these allowances in the period they are determined to be uncollectible.

Foreign Currency Translation:

The functional currency of a foreign subsidiary is the local currency. Assets and liabilities of foreign subsidiaries that use a currency other than U.S. dollars as their functional currency are translated to U.S. dollars at end of period currency exchange rates. The consolidated statements of operations of foreign subsidiaries are translated to U.S. dollars at average period currency exchange rates. The effect of translation for foreign subsidiaries is generally reported in Other Comprehensive Loss / Income. Foreign transaction gains and losses are immaterial.

Acquisition Costs:

Acquisition costs include period expenses, primarily professional services, related to acquisition activities.

Recent Accounting Pronouncements Affecting the Company:

In February 2016 the FASB issued ASU No. 2016-02, Leases (Topic 842). ASU No. 2016-02 requires the entity to recognize the assets and liabilities for the rights and obligations created by leased assets. Leases are to be classified as either finance or operating, with classification affecting expense recognition in the income statement. In July 2018 the FASB issued ASU No. 2018-10, Codification Improvements to Topic 842, Leases, and ASU No. 2018-11, Leases (Topic 842): Targeted Improvements, which provide supplemental adoption guidance and clarification to ASU No. 2016-02, which must be adopted concurrently with the adoption of ASU No. 2016-02 (ASU Nos. 2016-02, 2018‑10 and 2018-11 are collectively referred to as “Topic 842”). Topic 842 was effective for the Company in the first quarter of 2019 and is to be applied using either a modified retrospective approach or an optional transition method, which allows an entity to apply the new standard at the adoption date with a cumulative-effect adjustment to the opening balance of retained earnings in the period of adoption.

As further discussed at Note 5(e) - Leases, the Company adopted Topic 842 on January 1, 2019 under the optional transition method and elected the short-term lease exception and available practical expedients. Under the transition method, the Company did not adjust its comparative period financial information or make the new required lease disclosures for periods before the effective date.

In July 2017, the FASB issued ASU 2017-11, Accounting for Certain Financial Instruments with Down Round Features and Replacement of the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatorily Redeemable Noncontrolling Interests with a Scope Exception. Part I of this ASU addresses the complexity of accounting for certain financial instruments with down round features. Per the ASU, a freestanding equity-linked financial instrument (or embedded conversion option) no longer would be accounted for as a derivative liability at fair value as a result of the existence of a down round feature. The ASU is effective for public entities for fiscal years beginning after December 15, 2018 and the Company adopted it effective January 1, 2019. This ASU is applicable to the stock warrants issued as part of the Credit Agreement, as further discussed in Note 7 – Warrant.

Error Correction

As discussed in Note 3b – Revenue Recognition, the Company established an accounting policy to recognize freight and distribution expenses within cost of product sales. In connection with the closing of the Company’s books and the preparation and review of the financial statements for the quarter ended September 30, 2019, management noted that this accounting policy had not been correctly implemented and, as a result, the cost of freight and distribution expenses was netted within net product sales.

The following table presents the impact of adjustments to correctly reflect the adopted accounting policy. These adjustments (i) increase net product sales, total revenues, cost of product sales, total costs and expenses, cash received from customers and grants and cash paid to suppliers and employees by an equal amount within each period and (ii) have no impact on product margins, operating results, earnings per share, net assets, net cash used in operating activities, or equity in any period.

	Net Product Sales						Total Revenues						Cost of Product Sales						Total Costs and Expenses						Cash received from customers and grants						Cash paid to suppliers and employees
	As Filed		Adjustment		Revised		As Filed		Adjustment		Revised		As Filed		Adjustment		Revised		As Filed		Adjustment		Revised		As Filed		Adjustment		Revised		As Filed			Adjustment			Revised
2019:
3 months ended March 31	$	6,382,986	$	241,299	$	6,624,285	$	8,300,966	$	241,299	$	8,542,265	$	4,770,337	$	241,299	$	5,011,636	$	11,396,652	$	241,299	$	11,637,951	$	7,869,167	$	241,299	$	8,110,466	$	(12,349,126	)	$	(241,299	)	$	(12,590,425	)
3 months ended June 30		8,488,291		296,750		8,785,041		9,591,386		296,750		9,888,136		6,693,225		296,750		6,989,975		12,891,187		296,750		13,187,937		N/A		N/A		N/A		N/A			N/A			N/A
6 months ended June 30		14,871,277		538,049		15,409,326		17,892,352		538,049		18,430,401		11,463,562		538,049		12,001,611		24,287,839		538,049		24,825,888		17,627,823		538,049		18,165,872		(24,421,683	)		(538,049	)		(24,959,732	)

2018:
3 months ended March 31		6,398,227		307,813		6,706,040		7,717,132		307,813		8,024,945		4,117,779		307,813		4,425,592		8,371,450		307,813		8,679,263		6,039,385		307,813		6,347,198		(8,358,631	)		(307,813	)		(8,666,444	)
3 months ended June 30		6,857,861		240,456		7,098,317		8,720,326		240,456		8,960,782		5,935,428		240,456		6,175,884		10,474,056		240,456		10,714,512		N/A		N/A		N/A		N/A			N/A			N/A
6 months ended June 30		13,256,088		548,269		13,804,357		16,437,458		548,269		16,985,727		10,053,207		548,269		10,601,476		18,845,506		548,269		19,393,775		12,247,228		548,269		12,795,497		(17,352,226	)		(548,269	)		(17,900,495	)
3 months ended Sept. 30		7,856,038		448,332		8,304,370		9,376,793		448,332		9,825,125		6,774,749		448,332		7,223,081		11,706,630		448,332		12,154,962		N/A		N/A		N/A		N/A			N/A			N/A
9 months ended Sept. 30		21,112,126		996,601		22,108,727		25,814,251		996,601		26,810,852		16,827,956		996,601		17,824,557		30,552,135		996,601		31,548,736		20,816,327		996,601		21,812,928		(28,389,820	)		(996,601	)		(29,386,421	)
Year ended Dec. 31		26,741,020		1,172,189		27,913,209		33,409,251		1,172,189		34,581,440		21,427,243		1,172,189		22,599,432		41,391,919		1,172,189		42,564,108		28,632,084		1,172,189		29,804,273		(40,452,110	)		(1,172,189	)		(41,624,299	)

2017:
Year ended Dec. 31		19,322,302		1,193,524		20,515,826		24,015,427		1,193,524		25,208,951		12,921,157		1,193,524		14,114,681		30,497,977		1,193,524		31,691,501		24,971,299		1,193,524		26,164,823		(30,028,299	)		(1,193,524	)		(31,221,823	)

STOCKHOLDERS' EQUITY	9 Months Ended
STOCKHOLDERS' EQUITY	Sep. 30, 2019
STOCKHOLDERS' EQUITY [Abstract]
STOCKHOLDERS' EQUITY	NOTE 4 — STOCKHOLDERS’ EQUITY: During the first nine months of 2019, options to purchase 46,875 shares of the Company’s common stock were exercised on a cashless basis into 24,075 shares of common stock. During the first nine months of 2018, options to purchase 114,947 shares of the Company’s common stock were exercised on a cashless basis into 71,290 shares of common stock. On February 13, 2018, the Company closed on an underwritten registered public offering of 1,783,760 shares of its common stock at a public offering price of $6.75 per share for gross proceeds of approximately $12.0 million. The net proceeds, after underwriting discounts and commissions, were $10.9 million. The net proceeds were intended for business expansion and working capital, including product development; operational expansion or improvements, such as new automated equipment and a facilities update; clinical trials and other related activities; and, sales and marketing.

COMMITMENTS, CONTINGENCIES, AND CONCENTRATIONS

9 Months Ended

Sep. 30, 2019

COMMITMENTS, CONTINGENCIES, AND CONCENTRATIONS [Abstract]

COMMITMENTS, CONTINGENCIES, AND CONCENTRATIONS

NOTE 5 — COMMITMENTS, CONTINGENCIES, AND CONCENTRATIONS:

Concentrations:

The following table discloses product sales the Company had to each customer that purchased in excess of 10% of the Company’s net product sales for the periods indicated:

	For the three months ended										For the nine months ended										Accounts Receivable as of
	September 30, 2019					September 30, 2018					September 30, 2019					September 30, 2018					September 30, 2019		Dec. 31, 2018
	Sales		% of Sales			Sales		% of Sales			Sales		% of Sales			Sales		% of Sales
Customer 1	$	3,966,142		46.6	%	$	3,256,390		39	%	$	10,012,644		42.8	%	$	9,241,445		42	%	$	2,209,986	$	3,499,340
Customer 2		-		-	%		1,852,186		22	%		4,378,773		18.7	%		3,312,816		15	%		189,283		1,033,824

Sales include product sales only, while accounts receivable reflects the total due from the customer, including freight.

The following table discloses purchases the Company made from each vendor that sold to the Company in excess of 10% of the Company’s total purchases for the periods indicated:

For the three months ended

For the nine months ended

Accounts Payable as of

September 30, 2019

September 30, 2018

September 30, 2019

September 30, 2018

September 30, 2019

Dec. 31, 2018

Purchases

% of Purc.

Purchases

% of Purc.

Purchases

% of Purc.

Purchases

% of Purc.

Vendor 1

508,646

1,372,521

In the table above, an asterisk (*) indicates that purchases from the vendor did not exceed 10% for the period indicated or that accounts payable by the vendor did not exceed 10% of total accounts payable at the date indicated.

The Company currently buys materials that are purchased under intellectual property rights agreements and are important components in its products. Management believes that other suppliers could provide similar materials on comparable terms as the vendors shown in this table. A change in suppliers, however, could cause a delay in manufacturing, either from the logistics of changing suppliers or from product changes attributable to new components, which could result in a possible loss of sales, and which could adversely affect operating results.

Governmental Regulation:

All of the Company’s existing and proposed diagnostic products are regulated by the U.S. Food and Drug Administration, U.S. Department of Agriculture, certain U.S., state and local agencies, and/or comparable regulatory bodies in other countries. Most aspects of development, production, and marketing, including product testing, authorizations to market, labeling, promotion, manufacturing, and record keeping, are subject to regulatory review. After marketing approval has been granted, Chembio must continue to comply with governmental regulations. Failure to comply with applicable requirements can lead to sanctions, including withdrawal of products from the market, recalls, refusal to authorize government contracts, product seizures, civil money penalties, injunctions, and criminal prosecution.

Employment Contracts:

The Company has multi-year contracts with two key employees that call for salaries presently aggregating $820,000 per year. The contracts expire in March 2020 and December 2021. The following table is a schedule of future minimum salary commitments as of September 30, 2019:

2019	$	205,000
2020		478,800
2021		365,000

Pension Plan:

The Company has a 401(k) plan established for its employees whereby it matches 40% of the first 5% of salary (or up to 2% of salary) that an employee contributes to the plan. Matching contribution expenses totaled approximately $74,600 and $71,900 for the nine months ended September 30, 2019 and 2018, respectively.

Leases:

Chembio’s leases have historically been limited to its facilities in New York, Germany, and Malaysia. As of September 30, 2019, the Company was a party to seven leases. One of the leases is subject to a sublease for the remainder of its term, as further described below.

The Company’s leases generally include optional renewal periods. Upon entering into a new lease, the Company evaluates the leasehold improvements and regulatory requirements related to its operations in that location. To the extent that the initial lease term of the related lease is less than the useful life of the leasehold improvements and potential regulatory costs associated with moving the facility, the Company concludes that it is reasonably certain that a renewal option will be exercised, and thus that renewal period is included in the lease term and the related payments are reflected in the right-of-use (“ROU”) asset and lease liability.

The Company’s leases generally include fixed rental payments with defined annual increases. While certain of the Company’s leases are gross leases, the majority of the Company’s leases are net leases in which the Company makes separate payments to the lessor based on the lessor’s property and casualty insurance costs, the property taxes assessed on the property, and a portion of the common area maintenance where applicable. The Company has elected the practical expedient not to separate lease and nonlease components for all of the Company’s facility leases. The Company has also elected the practical expedient for short-term lease exception for all of its facility leases.

The components of lease expense for the three and nine months ended September 30, 2019 were as follows:

	Three Months Ended		Nine Months Ended
	September 30, 2019		September 30, 2019
Operating lease expense	$	425,757	$	1,108,016

Finance lease cost
Amortization of right-of-use assets	$	11,686	$	11,686
Interest on lease liabilities		4,033		4,033
Total finance lease expense	$	15,719	$	15,719

Supplemental cash flow information related to leases was as follows.

	Three Months Ended		Nine Months Ended
	September 30, 2019		September 30, 2019
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows for operating leases	$	158,050	$	474,150
Operating cash flows for finance leases		4,033		4,033
Financing cash flows for finance leases		9,851		9,851
Right-of-use assets obtained in exchange for lease obligations:
Operating leases	$	-	$	6,697,896
Finance leases		-		222,036

Supplemental balance sheet information related to leases was as follows:

	September 30, 2019
Operating Leases
Operating lease right-of-use assets	$	6,697,896

Current portion of operating lease liability		255,030
Operating lease liabilities		6,706,918
Total operating lease liabilities	$	6,961,948

Finance Leases
Finance lease right of use asset	$	233,722
Accumulated depreciation		(11,686	)
Finance lease right of use asset, net	$	222,036

Current portion of finance lease liability		41,169
Finance lease liability		182,702
Total finance lease liabilities	$	223,871

Weighted Average Remaining Lease Term
Operating leases	9.9 years
Finance leases	4.8 years

Weighted Average Discount Rate
Operating leases		8.51	%
Finance leases		7.00	%

During the nine months ended September 30, 2019, the Company executed an operating sublease related to its former Holbrook, New York facility. The sublease runs conterminously with the base lease in Holbrook, for which the Company remains primarily responsible. In addition, the Company entered into a finance lease agreement relating to the office furniture in June 2019. The Company recognized the corresponding lease asset and liability effective June 30, 2019 and recorded related depreciation starting on July 1, 2019. Monthly payments towards this lease commenced in July 2019.

At the time of the assessment, the Company did not have an established incremental borrowing rate and the interest rates implicit in each of the leases were not readily determinable, therefore the Company used an interest rate based on the market place for the public debt. In September 2019, the Company has entered into a credit agreement for a $20 million term loan as described on Note 6 - Long Term Debt.

Maturities of lease liabilities as of September 30, 2019 were as follows.

	Operating Leases		Finance Leases
2019	$	158,050	$	13,884
2020		813,443		55,536
2021		998,071		55,536
2022		1,026,044		55,536
2023		1,011,085		55,536
Thereafter		6,792,762		27,767
Total lease payments	$	10,799,455	$	263,795
Less: imputed interest		3,837,507		39,924
Total	$	6,961,948	$	223,871

As previously disclosed in the Company’s 2018 Annual Report on Form 10-K, and under the previous lease accounting standard, future minimum lease payments for operating leases having initial or remaining non-cancellable lease terms in excess of one year would have been as follows for the years ending December 31:

2019	$	384,308
2020		88,576
2021		-
	$	472,884

Litigation:

From time to time, the Company is involved in certain legal actions arising in the ordinary course of business. The outcomes of such actions, either individually or in the aggregate, are not expected to have a material adverse effect on the Company’s future financial position or results of operations.

LONG-TERM DEBT	9 Months Ended
LONG-TERM DEBT	Sep. 30, 2019
LONG-TERM DEBT [Abstract]
LONG-TERM DEBT	NOTE 6 — LONG-TERM DEBT: In September 2017, the Company entered into an agreement with an equipment vendor to purchase automated assembly equipment for approximately $660,000. The terms call for payments of 30% down, 60% at time of factory acceptance testing and 10% after delivery. The vendor agreed to lend the Company 15%, 40%, and 10% of each originally scheduled payment, respectively. The Company paid interest at an annual rate of 12% until delivery. Beginning in September 2018, the Company began making monthly payments of principal and interest of approximately $20,150, at an annual rate of 12% over a twenty-four month period. On September 3, 2019, the Company entered into a Credit Agreement and Guaranty (the “Credit Agreement”) with Perceptive Credit Holdings II, LP (the “Lender”). The Credit Agreement provides for a $20,000,000 senior secured term loan credit facility, which was drawn in full on September 4, 2019. Under the terms of the Credit Agreement, the Company may use the proceeds (i) for general working capital purposes and other permitted corporate purposes, (ii) to refinance certain of the Company’s existing indebtedness and (iii) to pay fees, costs and expenses incurred in connection with the Credit Agreement, including the Lender’s closing cost amount of $550,000, which was netted from the proceeds, and a financing fee of $600,000 (3.0% of gross proceeds) payable to Craig-Hallum Capital Group LLC, the Company’s financial advisor for the financing. Principal outstanding under the Credit Agreement bears interest at a rate per annum equal to the sum of (a) the greater of the one-month London Interbank Offered Rate and 2.5% plus (b) 8.75%. At any time at which an event of default has occurred and is continuing, the interest rate will increase by 4.0%. Accrued interest is payable on a monthly basis. No principal repayments are due under the Credit Agreement prior to September 30, 2022, unless the Company elects to prepay principal or principal is accelerated pursuant to an event of default identified in the Credit Agreement. Principal installments in the amount of $300,000 are payable on the last day of each of the eleven months from September 2022 through July 2023, and all remaining principal is payable at maturity on September 3, 2023. The Company may prepay outstanding principal from time to time, subject to payment of a premium on the prepaid principal amount equal to 10% through September 3, 2020, 8% from September 4, 2020 through September 3, 2021, and 4% from September 4, 2021 through September 3, 2022. No premium will be due with respect to any prepayment made on or after September 4, 2022. As of September 30, 2019, the loan balance, net of unamortized discounts and debt issuance costs, was $17.5 million and the company was in compliance with its loan covenants. Our obligations under the Credit Agreement are secured by a first priority, perfected lien on substantially all of our property and assets, including our equity interests in our subsidiaries.

WARRANT

9 Months Ended

Sep. 30, 2019

WARRANT [Abstract]

WARRANT

NOTE 7 — WARRANT:

In connection with entering into the Credit Agreement, on September 3, 2019, the Company issued to the Lender a seven-year warrant (the “Warrant”) to purchase up to 550,000 shares of the Company’s common stock at a per-share exercise price of $5.22. The Warrant is exercisable for cash or on a net, or “cashless,” basis, and the exercise price of the Warrant is subject to price-based, weighted-average antidilution adjustments for one year after issuance.

The Warrant was evaluated by the Company and classified to stockholder’s equity. Itsfair value was estimated using aBlack-Scholes option-pricing model using the assumptions below.

Stock price on issuance date	$	5.40
Strike Price	$	5.22
Risk-free interest rate		1.45	%
Volatility		43.65	%
Expected life		7 years

The fair value of the Warrant was determined to be approximately $1.4 million at $2.49 per share.

As of September 30, 2019 the balance recorded in the Company’s Stockholders’ Equity for the Warrants, net of allocated issuance costs, was $1.2M.

As of September 30, 2019, no warrants were exercised and no warrants have expired.

SUBSEQUENT EVENTS	9 Months Ended
SUBSEQUENT EVENTS	Sep. 30, 2019
SUBSEQUENT EVENTS [Abstract]
SUBSEQUENT EVENTS	NOTE 8 — SUBSEQUENT EVENTS: The Company and its newly formed subsidiary Chembio Diagnostics Brazil LLC entered into a definitive agreement to purchase all of the outstanding equity securities of Orangelife Comercio e Industria Ltda (“Orangelife”), a Brazilian manufacturer and distributor of point-of-care diagnostic tests for infectious diseases. Chembio will deliver $150,000 in cash and 153,707 common shares at closing to the former Orangelife equity holders , and will deliver up to an additional 497,288 common shares based on the achievement of certain milestones between 2020 and 2022. Subject to customary closing conditions, the transaction is expected to close during the fourth quarter of 2019.

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)

9 Months Ended

Sep. 30, 2019

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES [Abstract]

Basis of Presentation

Basis of Presentation:

Revenue Recognition

Revenue Recognition:

The Company adopted the standards for contracts that were not completed at the date of initial application (January 1, 2018).

Product Revenues

Reserves for Discounts and Allowances

Royalty Revenues

R&D and Grant Revenue

Disaggregation of Revenue

The following tables disaggregate total revenues:

	For the three months ended September 30, 2019						For the three months ended September 30, 2018
	Exchange Transactions		Non-Exchange Transactions		Total		Exchange Transactions		Non-Exchange Transactions		Total
Net product sales	$	8,510,629	$	-	$	8,510,629	$	8,304,370	$	-	$	8,304,370
License and royalty revenue		238,330		-		238,330		228,553		-		228,553
R&D and grant revenue		880,458		91,522		971,980		960,332		331,870		1,292,202
	$	9,629,417	$	91,522	$	9,720,939	$	9,493,255	$	331,870	$	9,825,125

					Total						Total
Africa					$	1,250,063					$	3,193,098
Asia						505,379						216,527
Europe & Middle East						1,629,965						1,666,066
Latin America						4,296,903						3,404,623
United States						2,038,629						1,344,811
					$	9,720,939					$	9,825,125

	For the nine months ended September 30, 2019						For the nine months ended September 30, 2018
	Exchange Transactions		Non-Exchange Transactions		Total		Exchange Transactions		Non-Exchange Transactions		Total
Net product sales	$	23,381,906	$	-	$	23,381,906	$	22,108,727	$	-	$	22,108,727
License and royalty revenue		703,352		-		703,352		707,010		-		707,010
R&D and grant revenue		2,272,454		1,255,579		3,528,033		2,328,058		1,667,057		3,995,115
	$	26,357,712	$	1,255,579	$	27,613,291	$	25,143,795	$	1,667,057	$	26,810,852

					Total						Total
Africa					$	6,009,103					$	7,156,822
Asia						746,025						1,212,839
Europe & Middle East						4,880,744						3,831,580
Latin America						9,981,874						9,743,764
United States						5,995,545						4,865,847
					$	27,613,291					$	26,810,852

Exchange transactions are recognized in accordance with ASU No. 2014-09, and non-exchange transactions are recognized in accordance with ASU No. 2018-08.

Contract Liabilities

Inventories

Inventories consist of the following at:

	September 30, 2019		December 31, 2018
Raw materials	$	2,653,368	$	2,803,677
Work in process		1,313,045		263,043
Finished goods		4,442,931		4,784,502
	$	8,409,344	$	7,851,222

Loss Per Share

Loss Per Share:

Stock Incentive Plan

Stock Incentive Plan:

Stock-Based Compensation

Stock-Based Compensation:

Stock-based compensation expense recognized in the condensed consolidated statements of operations was classified as follows:

	For the three months ended				For the nine months ended
	September 30, 2019		September 30, 2018		September 30, 2019		September 30, 2018
Cost of product sales	$	2,691	$	5,800	$	8,479	$	19,800
Research and development expenses		56,251		3,600		172,346		19,000
Selling, general and administrative expenses		447,646		65,359		1,050,141		260,244
	$	506,588	$	74,759	$	1,230,966	$	299,044

The weighted-average assumptions made in calculating the fair values of options are as follows:

	For the three months ended						For the nine months ended
	September 30, 2019			September 30, 2018			September 30, 2019			September 30, 2018
Expected term (in years)		N/A			4.5			N/A			4.9
Expected volatility		N/A	%		39.69	%		N/A	%		39.91	%
Expected dividend yield		N/A	%		0	%		N/A	%		0	%
Risk-free interest rate		N/A	%		2.70	%		N/A	%		2.70	%

The following table provides stock option activity for the nine months ended September 30, 2019:

Stock Options	Number of Shares		Weighted Average Exercise Price per Share		Weighted Average Remaining Contract Term	Aggregate Intrinsic Value
Outstanding at December 31, 2018		711,968	$	5.62	3.33 years	$	687,364

Granted		-		-			-
Exercised		46,875		3.48			172,242
Forfeited/expired/cancelled		15,000		5.68			30,286
Outstanding at September 30, 2019		650,093	$	5.77	2.79 years	$	730,142
Exercisable at September 30, 2019		447,759	$	4.98	2.16 years	$	713,762

The following table summarizes information about stock options outstanding at September 30, 2019:

	Stock Options Outstanding								Stock Options Exercisable
Range of Exercise Prices	Number of Shares		Average Remaining Contract Term (Year)		Weighted Average Exercise Price		Aggregate Intrinsic Value		Number of Shares		Weighted Average Exercise Price		Aggregate Intrinsic Value
1 to 2.79999		-		-	$	-	$	-		-	$	-	$	-
2.8 to 4.59999		257,468		1.41		3.44		689,143		257,468		3.44		689,143
4.6 to 6.39999		137,875		2.70		5.87		40,999		87,125		5.89		24,619
6.4 to 8.19999		207,875		4.31		7.31		-		84,416		7.32		-
8.2 to 12		46,875		3.85		11.45		-		18,750		11.45		-
Total		650,093		2.79	$	5.77	$	730,142		447,759	$	4.98	$	713,762

The following table summarizes information about restricted stock and restricted stock units outstanding as of September 30, 2019:

	Number of Shares & Units		Weighted Average Grant Date Fair Value
Outstanding at December 31, 2018		287,564	$	9.65

Granted		375,000		5.80
Earned/released		-		-
Forfeited/expired/cancelled		-		-
Outstanding at September 30, 2019		662,564	$	7.47

Geographic Information and Economic Dependency

	For the three months ended				For the nine months ended
	September 30, 2019		September 30, 2018		September 30, 2019		September 30, 2018
Africa	$	1,250,063	$	3,193,098	$	6,009,103	$	7,156,822
Asia		505,379		216,527		746,025		1,212,839
Europe & Middle East		1,027,147		728,073		2,946,813		1,773,872
Latin America		4,296,904		3,404,683		9,981,874		9,743,764
United States		1,431,136		761,989		3,698,091		2,221,430
	$	8,510,629	$	8,304,370	$	23,381,906	$	22,108,727

Long-lived assets by geographic area were as follows at:

	September 30, 2019		December 31, 2018
Asia		419,719		466,185
Europe & Middle East		157,257		123,752
United States		4,668,818		2,283,983
	$	5,245,794	$	2,873,920

Fair Value of Financial Instruments

Fair Value of Financial Instruments:

Level 1:

Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities;

Level 2:

Quoted prices in markets that are not active, or inputs which are observable, either directly or indirectly, for substantially the full term of the asset or liability; and,

Level 3:

Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (i.e., supported by little or no market activity).

Accounts Payable and Accrued Liabilities

Accounts Payable and Accrued Liabilities:

Accounts payable and accrued liabilities consisted of:

	September 30, 2019		December 31, 2018
Accounts payable – suppliers	$	2,975,913	$	3,622,765
Accrued commissions and royalties		819,405		867,344
Accrued payroll		320,266		48,867
Accrued vacation		659,358		264,789
Accrued bonuses		497,190		494,318
Accrued expenses – other		173,824		590,598
TOTAL	$	5,445,956	$	5,888,681

Goodwill Long-Lived Assets and Intangible Assets

Goodwill Long-Lived Assets and Intangible Assets:

The following table reflects changes in goodwill:

Beginning balance at December 31, 2018	$	4,983,127
Chembio Diagnostics GmbH measurement period adjustment		(145,760	)
Change in foreign currency exchange rate		(155,856	)
Balance at September 30, 2019	$	4,681,511

Intangible assets consisted of the following at:

	September 30, 2019							December 31, 2018
	Weighted Average Remaining Useful Life	Cost		Accumulated Amortization		Net Book Value		Cost		Accumulated Amortization		Net Book Value
Intellectual property	6	$	1,203,121	$	258,045	$	945,076	$	1,089,688	$	173,633	$	916,055
Developed technology	6		1,816,190		194,592		1,621,598		1,910,315		-		1,910,315
Customer contracts/relationships	8		1,093,521		231,894		861,627		1,121,600		151,929		969,671
Trade names	8		107,057		26,764		80,293		108,521		19,731		88,790
		$	4,219,889	$	711,295	$	3,508,594	$	4,230,124	$	345,293	$	3,884,831

No impairment of goodwill, long-lived tangible, and intangible assets was recorded for the nine months ended September 30, 2019 and 2018.

Taxes

Taxes:

R&D

R&D:

Allowance for Doubtful Accounts

Allowance for Doubtful Accounts:

Foreign Currency Translation

Foreign Currency Translation:

Acquisition Costs

Acquisition Costs:

Acquisition costs include period expenses, primarily professional services, related to acquisition activities.

Recent Accounting Pronouncements Affecting the Company

Recent Accounting Pronouncements Affecting the Company:

Error Correction

	Net Product Sales						Total Revenues						Cost of Product Sales						Total Costs and Expenses						Cash received from customers and grants						Cash paid to suppliers and employees
	As Filed		Adjustment		Revised		As Filed		Adjustment		Revised		As Filed		Adjustment		Revised		As Filed		Adjustment		Revised		As Filed		Adjustment		Revised		As Filed			Adjustment			Revised
2019:
3 months ended March 31	$	6,382,986	$	241,299	$	6,624,285	$	8,300,966	$	241,299	$	8,542,265	$	4,770,337	$	241,299	$	5,011,636	$	11,396,652	$	241,299	$	11,637,951	$	7,869,167	$	241,299	$	8,110,466	$	(12,349,126	)	$	(241,299	)	$	(12,590,425	)
3 months ended June 30		8,488,291		296,750		8,785,041		9,591,386		296,750		9,888,136		6,693,225		296,750		6,989,975		12,891,187		296,750		13,187,937		N/A		N/A		N/A		N/A			N/A			N/A
6 months ended June 30		14,871,277		538,049		15,409,326		17,892,352		538,049		18,430,401		11,463,562		538,049		12,001,611		24,287,839		538,049		24,825,888		17,627,823		538,049		18,165,872		(24,421,683	)		(538,049	)		(24,959,732	)

2018:
3 months ended March 31		6,398,227		307,813		6,706,040		7,717,132		307,813		8,024,945		4,117,779		307,813		4,425,592		8,371,450		307,813		8,679,263		6,039,385		307,813		6,347,198		(8,358,631	)		(307,813	)		(8,666,444	)
3 months ended June 30		6,857,861		240,456		7,098,317		8,720,326		240,456		8,960,782		5,935,428		240,456		6,175,884		10,474,056		240,456		10,714,512		N/A		N/A		N/A		N/A			N/A			N/A
6 months ended June 30		13,256,088		548,269		13,804,357		16,437,458		548,269		16,985,727		10,053,207		548,269		10,601,476		18,845,506		548,269		19,393,775		12,247,228		548,269		12,795,497		(17,352,226	)		(548,269	)		(17,900,495	)
3 months ended Sept. 30		7,856,038		448,332		8,304,370		9,376,793		448,332		9,825,125		6,774,749		448,332		7,223,081		11,706,630		448,332		12,154,962		N/A		N/A		N/A		N/A			N/A			N/A
9 months ended Sept. 30		21,112,126		996,601		22,108,727		25,814,251		996,601		26,810,852		16,827,956		996,601		17,824,557		30,552,135		996,601		31,548,736		20,816,327		996,601		21,812,928		(28,389,820	)		(996,601	)		(29,386,421	)
Year ended Dec. 31		26,741,020		1,172,189		27,913,209		33,409,251		1,172,189		34,581,440		21,427,243		1,172,189		22,599,432		41,391,919		1,172,189		42,564,108		28,632,084		1,172,189		29,804,273		(40,452,110	)		(1,172,189	)		(41,624,299	)

2017:
Year ended Dec. 31		19,322,302		1,193,524		20,515,826		24,015,427		1,193,524		25,208,951		12,921,157		1,193,524		14,114,681		30,497,977		1,193,524		31,691,501		24,971,299		1,193,524		26,164,823		(30,028,299	)		(1,193,524	)		(31,221,823	)

ACQUISITION (Tables)

9 Months Ended

Sep. 30, 2019

ACQUISITION [Abstract]

Fair Values of Assets Acquired and Liabilities Assumed

The following table summarizes the preliminary allocation of the purchase price to the estimated fair values of the assets acquired and liabilities assumed on the closing date of November 6, 2018:

	Amount
Net current assets	$	404,204
Property, plant and equipment		125,000
Goodwill		3,337,000
Deferred tax liability		(635,000	)
Other intangible assets (estimated useful life):
Developed technology (7 years)		1,900,000
Customer contracts / relationships (10 years)		360,000
Total consideration	$	5,491,204

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)

9 Months Ended

Sep. 30, 2019

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES [Abstract]

Disaggregation of Revenue

The following tables disaggregate total revenues:

	For the three months ended September 30, 2019						For the three months ended September 30, 2018
	Exchange Transactions		Non-Exchange Transactions		Total		Exchange Transactions		Non-Exchange Transactions		Total
Net product sales	$	8,510,629	$	-	$	8,510,629	$	8,304,370	$	-	$	8,304,370
License and royalty revenue		238,330		-		238,330		228,553		-		228,553
R&D and grant revenue		880,458		91,522		971,980		960,332		331,870		1,292,202
	$	9,629,417	$	91,522	$	9,720,939	$	9,493,255	$	331,870	$	9,825,125

					Total						Total
Africa					$	1,250,063					$	3,193,098
Asia						505,379						216,527
Europe & Middle East						1,629,965						1,666,066
Latin America						4,296,903						3,404,623
United States						2,038,629						1,344,811
					$	9,720,939					$	9,825,125

	For the nine months ended September 30, 2019						For the nine months ended September 30, 2018
	Exchange Transactions		Non-Exchange Transactions		Total		Exchange Transactions		Non-Exchange Transactions		Total
Net product sales	$	23,381,906	$	-	$	23,381,906	$	22,108,727	$	-	$	22,108,727
License and royalty revenue		703,352		-		703,352		707,010		-		707,010
R&D and grant revenue		2,272,454		1,255,579		3,528,033		2,328,058		1,667,057		3,995,115
	$	26,357,712	$	1,255,579	$	27,613,291	$	25,143,795	$	1,667,057	$	26,810,852

					Total						Total
Africa					$	6,009,103					$	7,156,822
Asia						746,025						1,212,839
Europe & Middle East						4,880,744						3,831,580
Latin America						9,981,874						9,743,764
United States						5,995,545						4,865,847
					$	27,613,291					$	26,810,852

Inventories

Inventories consist of the following at:

	September 30, 2019		December 31, 2018
Raw materials	$	2,653,368	$	2,803,677
Work in process		1,313,045		263,043
Finished goods		4,442,931		4,784,502
	$	8,409,344	$	7,851,222

Stock-Based Compensation Expense

Stock-based compensation expense recognized in the condensed consolidated statements of operations was classified as follows:

	For the three months ended				For the nine months ended
	September 30, 2019		September 30, 2018		September 30, 2019		September 30, 2018
Cost of product sales	$	2,691	$	5,800	$	8,479	$	19,800
Research and development expenses		56,251		3,600		172,346		19,000
Selling, general and administrative expenses		447,646		65,359		1,050,141		260,244
	$	506,588	$	74,759	$	1,230,966	$	299,044

Assumptions Made in Calculating Fair Values of Options

The weighted-average assumptions made in calculating the fair values of options are as follows:

	For the three months ended						For the nine months ended
	September 30, 2019			September 30, 2018			September 30, 2019			September 30, 2018
Expected term (in years)		N/A			4.5			N/A			4.9
Expected volatility		N/A	%		39.69	%		N/A	%		39.91	%
Expected dividend yield		N/A	%		0	%		N/A	%		0	%
Risk-free interest rate		N/A	%		2.70	%		N/A	%		2.70	%

Stock Option Activity

The following table provides stock option activity for the nine months ended September 30, 2019:

Stock Options	Number of Shares		Weighted Average Exercise Price per Share		Weighted Average Remaining Contract Term	Aggregate Intrinsic Value
Outstanding at December 31, 2018		711,968	$	5.62	3.33 years	$	687,364

Granted		-		-			-
Exercised		46,875		3.48			172,242
Forfeited/expired/cancelled		15,000		5.68			30,286
Outstanding at September 30, 2019		650,093	$	5.77	2.79 years	$	730,142
Exercisable at September 30, 2019		447,759	$	4.98	2.16 years	$	713,762

Stock Options Outstanding

The following table summarizes information about stock options outstanding at September 30, 2019:

	Stock Options Outstanding								Stock Options Exercisable
Range of Exercise Prices	Number of Shares		Average Remaining Contract Term (Year)		Weighted Average Exercise Price		Aggregate Intrinsic Value		Number of Shares		Weighted Average Exercise Price		Aggregate Intrinsic Value
1 to 2.79999		-		-	$	-	$	-		-	$	-	$	-
2.8 to 4.59999		257,468		1.41		3.44		689,143		257,468		3.44		689,143
4.6 to 6.39999		137,875		2.70		5.87		40,999		87,125		5.89		24,619
6.4 to 8.19999		207,875		4.31		7.31		-		84,416		7.32		-
8.2 to 12		46,875		3.85		11.45		-		18,750		11.45		-
Total		650,093		2.79	$	5.77	$	730,142		447,759	$	4.98	$	713,762

Summary of Restricted Stock and Restricted Stock Units Outstanding

The following table summarizes information about restricted stock and restricted stock units outstanding as of September 30, 2019:

	Number of Shares & Units		Weighted Average Grant Date Fair Value
Outstanding at December 31, 2018		287,564	$	9.65

Granted		375,000		5.80
Earned/released		-		-
Forfeited/expired/cancelled		-		-
Outstanding at September 30, 2019		662,564	$	7.47

Net Product Sales by Geographic Area

	For the three months ended				For the nine months ended
	September 30, 2019		September 30, 2018		September 30, 2019		September 30, 2018
Africa	$	1,250,063	$	3,193,098	$	6,009,103	$	7,156,822
Asia		505,379		216,527		746,025		1,212,839
Europe & Middle East		1,027,147		728,073		2,946,813		1,773,872
Latin America		4,296,904		3,404,683		9,981,874		9,743,764
United States		1,431,136		761,989		3,698,091		2,221,430
	$	8,510,629	$	8,304,370	$	23,381,906	$	22,108,727

Long-lived Assets by Geographic Area

Long-lived assets by geographic area were as follows at:

	September 30, 2019		December 31, 2018
Asia		419,719		466,185
Europe & Middle East		157,257		123,752
United States		4,668,818		2,283,983
	$	5,245,794	$	2,873,920

Accounts Payable and Accrued Liabilities

Accounts payable and accrued liabilities consisted of:

	September 30, 2019		December 31, 2018
Accounts payable – suppliers	$	2,975,913	$	3,622,765
Accrued commissions and royalties		819,405		867,344
Accrued payroll		320,266		48,867
Accrued vacation		659,358		264,789
Accrued bonuses		497,190		494,318
Accrued expenses – other		173,824		590,598
TOTAL	$	5,445,956	$	5,888,681

Changes in Goodwill

The following table reflects changes in goodwill:

Beginning balance at December 31, 2018	$	4,983,127
Chembio Diagnostics GmbH measurement period adjustment		(145,760	)
Change in foreign currency exchange rate		(155,856	)
Balance at September 30, 2019	$	4,681,511

Intangible Assets

Intangible assets consisted of the following at:

	September 30, 2019							December 31, 2018
	Weighted Average Remaining Useful Life	Cost		Accumulated Amortization		Net Book Value		Cost		Accumulated Amortization		Net Book Value
Intellectual property	6	$	1,203,121	$	258,045	$	945,076	$	1,089,688	$	173,633	$	916,055
Developed technology	6		1,816,190		194,592		1,621,598		1,910,315		-		1,910,315
Customer contracts/relationships	8		1,093,521		231,894		861,627		1,121,600		151,929		969,671
Trade names	8		107,057		26,764		80,293		108,521		19,731		88,790
		$	4,219,889	$	711,295	$	3,508,594	$	4,230,124	$	345,293	$	3,884,831

Error Correction

	Net Product Sales						Total Revenues						Cost of Product Sales						Total Costs and Expenses						Cash received from customers and grants						Cash paid to suppliers and employees
	As Filed		Adjustment		Revised		As Filed		Adjustment		Revised		As Filed		Adjustment		Revised		As Filed		Adjustment		Revised		As Filed		Adjustment		Revised		As Filed			Adjustment			Revised
2019:
3 months ended March 31	$	6,382,986	$	241,299	$	6,624,285	$	8,300,966	$	241,299	$	8,542,265	$	4,770,337	$	241,299	$	5,011,636	$	11,396,652	$	241,299	$	11,637,951	$	7,869,167	$	241,299	$	8,110,466	$	(12,349,126	)	$	(241,299	)	$	(12,590,425	)
3 months ended June 30		8,488,291		296,750		8,785,041		9,591,386		296,750		9,888,136		6,693,225		296,750		6,989,975		12,891,187		296,750		13,187,937		N/A		N/A		N/A		N/A			N/A			N/A
6 months ended June 30		14,871,277		538,049		15,409,326		17,892,352		538,049		18,430,401		11,463,562		538,049		12,001,611		24,287,839		538,049		24,825,888		17,627,823		538,049		18,165,872		(24,421,683	)		(538,049	)		(24,959,732	)

2018:
3 months ended March 31		6,398,227		307,813		6,706,040		7,717,132		307,813		8,024,945		4,117,779		307,813		4,425,592		8,371,450		307,813		8,679,263		6,039,385		307,813		6,347,198		(8,358,631	)		(307,813	)		(8,666,444	)
3 months ended June 30		6,857,861		240,456		7,098,317		8,720,326		240,456		8,960,782		5,935,428		240,456		6,175,884		10,474,056		240,456		10,714,512		N/A		N/A		N/A		N/A			N/A			N/A
6 months ended June 30		13,256,088		548,269		13,804,357		16,437,458		548,269		16,985,727		10,053,207		548,269		10,601,476		18,845,506		548,269		19,393,775		12,247,228		548,269		12,795,497		(17,352,226	)		(548,269	)		(17,900,495	)
3 months ended Sept. 30		7,856,038		448,332		8,304,370		9,376,793		448,332		9,825,125		6,774,749		448,332		7,223,081		11,706,630		448,332		12,154,962		N/A		N/A		N/A		N/A			N/A			N/A
9 months ended Sept. 30		21,112,126		996,601		22,108,727		25,814,251		996,601		26,810,852		16,827,956		996,601		17,824,557		30,552,135		996,601		31,548,736		20,816,327		996,601		21,812,928		(28,389,820	)		(996,601	)		(29,386,421	)
Year ended Dec. 31		26,741,020		1,172,189		27,913,209		33,409,251		1,172,189		34,581,440		21,427,243		1,172,189		22,599,432		41,391,919		1,172,189		42,564,108		28,632,084		1,172,189		29,804,273		(40,452,110	)		(1,172,189	)		(41,624,299	)

2017:
Year ended Dec. 31		19,322,302		1,193,524		20,515,826		24,015,427		1,193,524		25,208,951		12,921,157		1,193,524		14,114,681		30,497,977		1,193,524		31,691,501		24,971,299		1,193,524		26,164,823		(30,028,299	)		(1,193,524	)		(31,221,823	)

COMMITMENTS, CONTINGENCIES, AND CONCENTRATIONS (Tables)

9 Months Ended

Sep. 30, 2019

COMMITMENTS, CONTINGENCIES, AND CONCENTRATIONS [Abstract]

Customer and Purchase Concentration Risks

The following table discloses product sales the Company had to each customer that purchased in excess of 10% of the Company’s net product sales for the periods indicated:

	For the three months ended										For the nine months ended										Accounts Receivable as of
	September 30, 2019					September 30, 2018					September 30, 2019					September 30, 2018					September 30, 2019		Dec. 31, 2018
	Sales		% of Sales			Sales		% of Sales			Sales		% of Sales			Sales		% of Sales
Customer 1	$	3,966,142		46.6	%	$	3,256,390		39	%	$	10,012,644		42.8	%	$	9,241,445		42	%	$	2,209,986	$	3,499,340
Customer 2		-		-	%		1,852,186		22	%		4,378,773		18.7	%		3,312,816		15	%		189,283		1,033,824

Sales include product sales only, while accounts receivable reflects the total due from the customer, including freight.

The following table discloses purchases the Company made from each vendor that sold to the Company in excess of 10% of the Company’s total purchases for the periods indicated:

For the three months ended

For the nine months ended

Accounts Payable as of

September 30, 2019

September 30, 2018

September 30, 2019

September 30, 2018

September 30, 2019

Dec. 31, 2018

Purchases

% of Purc.

Purchases

% of Purc.

Purchases

% of Purc.

Purchases

% of Purc.

Vendor 1

508,646

1,372,521

Future Minimum Salary Commitment

The following table is a schedule of future minimum salary commitments as of September 30, 2019:

2019	$	205,000
2020		478,800
2021		365,000

Components of Lease Expense

The components of lease expense for the three and nine months ended September 30, 2019 were as follows:

	Three Months Ended		Nine Months Ended
	September 30, 2019		September 30, 2019
Operating lease expense	$	425,757	$	1,108,016

Finance lease cost
Amortization of right-of-use assets	$	11,686	$	11,686
Interest on lease liabilities		4,033		4,033
Total finance lease expense	$	15,719	$	15,719

Supplemental Cash Flow Information Related to Leases

Supplemental cash flow information related to leases was as follows.

	Three Months Ended		Nine Months Ended
	September 30, 2019		September 30, 2019
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows for operating leases	$	158,050	$	474,150
Operating cash flows for finance leases		4,033		4,033
Financing cash flows for finance leases		9,851		9,851
Right-of-use assets obtained in exchange for lease obligations:
Operating leases	$	-	$	6,697,896
Finance leases		-		222,036

Supplemental Balance Sheet Information Related to Leases

Supplemental balance sheet information related to leases was as follows:

	September 30, 2019
Operating Leases
Operating lease right-of-use assets	$	6,697,896

Current portion of operating lease liability		255,030
Operating lease liabilities		6,706,918
Total operating lease liabilities	$	6,961,948

Finance Leases
Finance lease right of use asset	$	233,722
Accumulated depreciation		(11,686	)
Finance lease right of use asset, net	$	222,036

Current portion of finance lease liability		41,169
Finance lease liability		182,702
Total finance lease liabilities	$	223,871

Weighted Average Remaining Lease Term
Operating leases	9.9 years
Finance leases	4.8 years

Weighted Average Discount Rate
Operating leases		8.51	%
Finance leases		7.00	%

Maturities of Lease Liabilities

Maturities of lease liabilities as of September 30, 2019 were as follows.

	Operating Leases		Finance Leases
2019	$	158,050	$	13,884
2020		813,443		55,536
2021		998,071		55,536
2022		1,026,044		55,536
2023		1,011,085		55,536
Thereafter		6,792,762		27,767
Total lease payments	$	10,799,455	$	263,795
Less: imputed interest		3,837,507		39,924
Total	$	6,961,948	$	223,871

Future Minimum Lease Payments

2019	$	384,308
2020		88,576
2021		-
	$	472,884

WARRANT (Tables)

9 Months Ended

Sep. 30, 2019

WARRANT [Abstract]

Warrants Fair Value Assumptions

The Warrant was evaluated by the Company and classified to stockholder’s equity. Itsfair value was estimated using aBlack-Scholes option-pricing model using the assumptions below.

Stock price on issuance date	$	5.40
Strike Price	$	5.22
Risk-free interest rate		1.45	%
Volatility		43.65	%
Expected life		7 years

ACQUISITION (Details) - USD ($)		3 Months Ended		9 Months Ended
ACQUISITION (Details) - USD ($)	Nov. 06, 2018	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018	Dec. 31, 2018
Business Combination, Consideration Transferred [Abstract]
Goodwill reduced due to routine post-closing adjustments				$ (145,760)
Acquisition costs		$ 0	$ 0	395,612	$ 0
Fair values of Assets Acquired and Liabilities Assumed [Abstract]
Goodwill		4,681,511		4,681,511		$ 4,983,127
opTricon [Member]
Business Combination, Consideration Transferred [Abstract]
Goodwill reduced due to routine post-closing adjustments				(145,760)
Acquisition costs		$ 0		$ 395,612
Fair values of Assets Acquired and Liabilities Assumed [Abstract]
Net current assets	$ 404,204
Property, plant and equipment	125,000
Goodwill	3,337,000
Deferred tax liability	(635,000)
Other intangible assets (estimated useful life):
Other intangible assets	2,260,000
Total consideration	5,491,204
opTricon [Member] \| Developed Technology [Member]
Other intangible assets (estimated useful life):
Other intangible assets	$ 1,900,000
Weighted average useful life	7 years
opTricon [Member] \| Customer Contracts / Relationships [Member]
Other intangible assets (estimated useful life):
Other intangible assets	$ 360,000
Weighted average useful life	10 years

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES, Part 1 (Details) - USD ($)	3 Months Ended						6 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Jun. 30, 2019	Jun. 30, 2018	Sep. 30, 2019	Sep. 30, 2018	Dec. 31, 2018	Dec. 31, 2017
Disaggregation of Revenue [Abstract]
Total revenues	$ 9,720,939	$ 9,888,136	$ 8,542,265	$ 9,825,125	$ 8,960,782	$ 8,024,945	$ 18,430,401	$ 16,985,727	$ 27,613,291	$ 26,810,852	$ 34,581,440	$ 25,208,951
Contract Liabilities [Abstract]
Deferred revenue	237,500								237,500		422,905
Earned grant revenue									422,905
Inventories [Abstract]
Raw materials	2,653,368								2,653,368		2,803,677
Work in process	1,313,045								1,313,045		263,043
Finished goods	4,442,931								4,442,931		4,784,502
Inventories	8,409,344								8,409,344		7,851,222
Inventory valuation reserves	67,000								67,000		78,000
Exchange Transactions [Member]
Disaggregation of Revenue [Abstract]
Total revenues	9,629,417			9,493,255					26,356,252	25,143,795
Non-Exchange Transactions [Member]
Disaggregation of Revenue [Abstract]
Total revenues	91,522			331,870					1,255,579	1,667,057
Africa [Member]
Disaggregation of Revenue [Abstract]
Total revenues	1,250,063			3,193,098					6,009,103	7,156,822
Asia [Member]
Disaggregation of Revenue [Abstract]
Total revenues	505,379			216,527					746,025	1,212,839
Europe & Middle East [Member]
Disaggregation of Revenue [Abstract]
Total revenues	1,629,965			1,666,066					4,880,744	3,831,580
Latin America [Member]
Disaggregation of Revenue [Abstract]
Total revenues	4,296,903			3,404,683					9,981,874	9,743,764
United States [Member]
Disaggregation of Revenue [Abstract]
Total revenues	2,038,629			1,344,811					5,995,545	4,865,847
Net Product Sales [Member]
Disaggregation of Revenue [Abstract]
Total revenues	8,510,629	$ 8,785,041	$ 6,624,285	8,304,370	$ 7,098,317	$ 6,706,040	$ 15,409,326	$ 13,804,357	23,381,906	22,108,727	$ 27,913,209	$ 20,515,826
Net Product Sales [Member] \| Exchange Transactions [Member]
Disaggregation of Revenue [Abstract]
Total revenues	8,510,629			8,304,370					23,381,906	22,108,727
Net Product Sales [Member] \| Non-Exchange Transactions [Member]
Disaggregation of Revenue [Abstract]
Total revenues	0			0					0	0
Net Product Sales [Member] \| Africa [Member]
Disaggregation of Revenue [Abstract]
Total revenues	1,250,063			3,193,098					6,009,103	7,156,822
Net Product Sales [Member] \| Asia [Member]
Disaggregation of Revenue [Abstract]
Total revenues	505,379			216,527					746,025	1,212,839
Net Product Sales [Member] \| Europe & Middle East [Member]
Disaggregation of Revenue [Abstract]
Total revenues	1,027,147			728,073					2,946,813	1,773,872
Net Product Sales [Member] \| Latin America [Member]
Disaggregation of Revenue [Abstract]
Total revenues	4,296,904			3,404,683					9,981,874	9,743,764
Net Product Sales [Member] \| United States [Member]
Disaggregation of Revenue [Abstract]
Total revenues	1,431,136			761,989					3,698,091	2,221,430
License and Royalty Revenue [Member]
Disaggregation of Revenue [Abstract]
Total revenues	238,330			228,553					703,352	707,010
License and Royalty Revenue [Member] \| Exchange Transactions [Member]
Disaggregation of Revenue [Abstract]
Total revenues	238,330			228,553					703,352	707,010
License and Royalty Revenue [Member] \| Non-Exchange Transactions [Member]
Disaggregation of Revenue [Abstract]
Total revenues	0			0					0	0
R&D and Grant Revenue [Member]
Disaggregation of Revenue [Abstract]
Total revenues	971,980			1,292,202					3,528,033	3,995,115
R&D and Grant Revenue [Member] \| Exchange Transactions [Member]
Disaggregation of Revenue [Abstract]
Total revenues	880,458			960,332					2,272,454	2,328,058
R&D and Grant Revenue [Member] \| Non-Exchange Transactions [Member]
Disaggregation of Revenue [Abstract]
Total revenues	$ 91,522			$ 331,870					$ 1,255,579	$ 1,667,057
Minimum [Member]
Product Revenue [Abstract]
Revenue, payment terms									30 days
Maximum [Member]
Product Revenue [Abstract]
Revenue, payment terms									60 days
Warrants [Member]
Loss Per Share [Abstract]
Antidilutive securities excluded from calculation of diluted earnings per share (in shares)	550,000
Options [Member]
Loss Per Share [Abstract]
Antidilutive securities excluded from calculation of diluted earnings per share (in shares)	650,093			693,116					672,472	709,042

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES, Part 2 (Details) - USD ($)		3 Months Ended		9 Months Ended		12 Months Ended
	Jun. 03, 2008	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018	Dec. 31, 2018	Sep. 30, 2019	Jun. 18, 2019	Jun. 19, 2014	Sep. 22, 2011
Share-based Arrangements with Employees and Nonemployees [Abstract]
Number of stock options issued under the plan (in shares)				46,875	114,947
Stock options, additional disclosure [Abstract]
Outstanding, aggregate intrinsic value, end of period		$ 730,142		$ 730,142
Exercisable, aggregate intrinsic value, end of period		713,762		$ 713,762
Stock Options Outstanding [Abstract]
Number of Shares (in shares)							650,093
Average remaining contract life				2 years 9 months 14 days
Weighted average exercise price (in dollars per share)							$ 5.77
Aggregate intrinsic value		730,142		$ 730,142			$ 730,142
Stock Options Exercisable [Abstract]
Number of Shares (in shares)							447,759
Weighted average exercise price (in dollars per share)							$ 4.98
Aggregate intrinsic value		713,762		713,762			$ 713,762
Employee Service Share-based Compensation, Aggregate Disclosures [Abstract]
Allocated share-based compensation expense		506,588	$ 74,759	1,230,966	$ 299,044
1 to 2.79999 [Member]
Stock options, additional disclosure [Abstract]
Outstanding, aggregate intrinsic value, end of period		0		0
Exercisable, aggregate intrinsic value, end of period		0		$ 0
Range of Exercise Prices [Abstract]
Range of exercise prices, minimum (in dollars per share)				$ 1
Range of exercise prices, maximum (in dollars per share)				$ 2.79999
Stock Options Outstanding [Abstract]
Number of Shares (in shares)							0
Average remaining contract life				0 years
Weighted average exercise price (in dollars per share)							$ 0
Aggregate intrinsic value		0		$ 0			$ 0
Stock Options Exercisable [Abstract]
Number of Shares (in shares)							0
Weighted average exercise price (in dollars per share)							$ 0
Aggregate intrinsic value		0		0			$ 0
2.8 to 4.59999 [Member]
Stock options, additional disclosure [Abstract]
Outstanding, aggregate intrinsic value, end of period		689,143		689,143
Exercisable, aggregate intrinsic value, end of period		689,143		$ 689,143
Range of Exercise Prices [Abstract]
Range of exercise prices, minimum (in dollars per share)				$ 2.8
Range of exercise prices, maximum (in dollars per share)				$ 4.59999
Stock Options Outstanding [Abstract]
Number of Shares (in shares)							257,468
Average remaining contract life				1 year 4 months 28 days
Weighted average exercise price (in dollars per share)							$ 3.44
Aggregate intrinsic value		689,143		$ 689,143			$ 689,143
Stock Options Exercisable [Abstract]
Number of Shares (in shares)							257,468
Weighted average exercise price (in dollars per share)							$ 3.44
Aggregate intrinsic value		689,143		689,143			$ 689,143
4.6 to 6.39999 [Member]
Stock options, additional disclosure [Abstract]
Outstanding, aggregate intrinsic value, end of period		40,999		40,999
Exercisable, aggregate intrinsic value, end of period		24,619		$ 24,619
Range of Exercise Prices [Abstract]
Range of exercise prices, minimum (in dollars per share)				$ 4.6
Range of exercise prices, maximum (in dollars per share)				$ 6.39999
Stock Options Outstanding [Abstract]
Number of Shares (in shares)							137,875
Average remaining contract life				2 years 8 months 12 days
Weighted average exercise price (in dollars per share)							$ 5.87
Aggregate intrinsic value		40,999		$ 40,999			$ 40,999
Stock Options Exercisable [Abstract]
Number of Shares (in shares)							87,125
Weighted average exercise price (in dollars per share)							$ 5.89
Aggregate intrinsic value		24,619		24,619			$ 24,619
6.4 to 8.19999 [Member]
Stock options, additional disclosure [Abstract]
Outstanding, aggregate intrinsic value, end of period		0		0
Exercisable, aggregate intrinsic value, end of period		0		$ 0
Range of Exercise Prices [Abstract]
Range of exercise prices, minimum (in dollars per share)				$ 6.4
Range of exercise prices, maximum (in dollars per share)				$ 8.19999
Stock Options Outstanding [Abstract]
Number of Shares (in shares)							207,875
Average remaining contract life				4 years 3 months 22 days
Weighted average exercise price (in dollars per share)							$ 7.31
Aggregate intrinsic value		0		$ 0			$ 0
Stock Options Exercisable [Abstract]
Number of Shares (in shares)							84,416
Weighted average exercise price (in dollars per share)							$ 7.32
Aggregate intrinsic value		0		0			$ 0
8.2 to 12 [Member]
Stock options, additional disclosure [Abstract]
Outstanding, aggregate intrinsic value, end of period		0		0
Exercisable, aggregate intrinsic value, end of period		0		$ 0
Range of Exercise Prices [Abstract]
Range of exercise prices, minimum (in dollars per share)				$ 8.2
Range of exercise prices, maximum (in dollars per share)				$ 12
Stock Options Outstanding [Abstract]
Number of Shares (in shares)							46,875
Average remaining contract life				3 years 10 months 6 days
Weighted average exercise price (in dollars per share)							$ 11.45
Aggregate intrinsic value		0		$ 0			$ 0
Stock Options Exercisable [Abstract]
Number of Shares (in shares)							18,750
Weighted average exercise price (in dollars per share)							$ 11.45
Aggregate intrinsic value		$ 0		$ 0			$ 0
Stock Options [Member]
Share-based Arrangements with Employees and Nonemployees [Abstract]
Number of stock options outstanding under the plan (in shares)		650,093		711,968		711,968	650,093
Assumptions made in calculating fair values of options [Abstract]
Expected term		0 years	4 years 6 months	0 years	4 years 10 months 24 days
Expected volatility		0.00%	39.69%	0.00%	39.91%
Expected dividend yield		0.00%	0.00%	0.00%	0.00%
Risk-free interest rate		0.00%	2.70%	0.00%	2.70%
Stock options, number of shares [Roll forward]
Outstanding, beginning of period (in shares)				711,968
Granted (in shares)				0
Exercised (in shares)				46,875
Forfeited/expired/cancelled (in shares)				15,000
Outstanding, end of period (in shares)		650,093		650,093		711,968
Exercisable, end of period (in shares)		447,759		447,759
Stock options, outstanding, weighted average exercise price per share [Roll Forward]
Outstanding, beginning of period (in dollars per share)				$ 5.62
Granted (in dollars per share)				0
Exercised (in dollars per share)				3.48
Forfeited/expired/cancelled (in dollars per share)				5.68
Outstanding, end of period (in dollars per share)		$ 5.77		5.77		$ 5.62
Exercisable, end of period (in dollars per share)		$ 4.98		$ 4.98
Stock options, additional disclosure [Abstract]
Outstanding, weighted average remaining contract term				2 years 9 months 14 days		3 years 3 months 29 days
Exercisable, weighted average remaining contract term				2 years 1 month 28 days
Outstanding, aggregate intrinsic value, beginning of period				$ 687,364
Granted, aggregate intrinsic value				0
Exercised, aggregate intrinsic value				172,242
Outstanding, aggregate intrinsic value, end of period		$ 730,142		730,142		$ 687,364
Exercisable, aggregate intrinsic value, end of period		713,762		$ 713,762
Net unrecognized compensation cost							$ 496,296
Weighted average period for recognition of net unrecognized compensation cost				1 year 9 months 25 days
Total fair value of stock options vested during period				$ 295,412	$ 379,384
Stock Options Outstanding [Abstract]
Aggregate intrinsic value		730,142		687,364		$ 687,364	730,142
Stock Options Exercisable [Abstract]
Aggregate intrinsic value		$ 713,762		$ 713,762			713,762
Weighted Average Grant Date Fair Value [Abstract]
Weighted average period for recognition of net unrecognized compensation cost				1 year 9 months 25 days
Restricted Stock and Restricted Stock Units [Member]
Share-based Arrangements with Employees and Nonemployees [Abstract]
Number of restricted shares awarded under the plan (in shares)				375,000
Stock options, additional disclosure [Abstract]
Weighted average period for recognition of net unrecognized compensation cost				2 years 5 months 1 day
Number of Shares & Units [Abstract]
Outstanding, beginning of period (in shares)				287,564
Granted (in shares)				375,000
Earned/released (in shares)				0
Forfeited/expired/cancelled (in shares)				0
Outstanding, end of period (in shares)		662,564		662,564		287,564
Weighted Average Grant Date Fair Value [Abstract]
Outstanding, beginning of period (in dollars per share)				$ 9.65
Granted (in dollars per share)				5.80
Earned/released (in dollars per share)				0
Forfeited/expired/cancelled (in dollars per share)				0
Outstanding, end of period (in dollars per share)		$ 7.47		$ 7.47		$ 9.65
Net unrecognized compensation cost							$ 3,639,325
Weighted average period for recognition of net unrecognized compensation cost				2 years 5 months 1 day
2008 Stock Incentive Plan [Member] \| Stock Options [Member]
Share-based Arrangements with Employees and Nonemployees [Abstract]
Number of shares authorized under the plan (in shares)	625,000									750,000
Number of stock options outstanding under the plan (in shares)		99,132		99,132			99,132
Increase in number of shares authorized (in shares)	125,000
Number of stock options issued under the plan (in shares)				508,889
Options or shares still available to be issued (in shares)							0
Stock options, number of shares [Roll forward]
Outstanding, end of period (in shares)		99,132		99,132
2014 Stock Incentive Plan [Member] \| Stock Options [Member]
Share-based Arrangements with Employees and Nonemployees [Abstract]
Number of shares authorized under the plan (in shares)									800,000
Number of stock options outstanding under the plan (in shares)		344,093		344,093			344,093
Number of stock options issued under the plan (in shares)				132,282
Options or shares still available to be issued (in shares)							0
Stock options, number of shares [Roll forward]
Outstanding, end of period (in shares)		344,093		344,093
2014 Stock Incentive Plan [Member] \| Restricted Stock [Member]
Share-based Arrangements with Employees and Nonemployees [Abstract]
Number of restricted shares awarded under the plan (in shares)						266,839
Number of Shares & Units [Abstract]
Granted (in shares)						266,839
2014 Stock Incentive Plan [Member] \| Restricted Stock Units (RSUs) [Member]
Share-based Arrangements with Employees and Nonemployees [Abstract]
Number of restricted shares awarded under the plan (in shares)						20,725
Number of Shares & Units [Abstract]
Granted (in shares)						20,725
2019 Omnibus Incentive Plan [Member] \| Stock Options [Member]
Share-based Arrangements with Employees and Nonemployees [Abstract]
Number of shares authorized under the plan (in shares)								2,400,000
Options or shares still available to be issued (in shares)							2,025,000
2019 Omnibus Incentive Plan [Member] \| Restricted Stock [Member]
Share-based Arrangements with Employees and Nonemployees [Abstract]
Number of restricted shares awarded under the plan (in shares)				375,000
Number of Shares & Units [Abstract]
Granted (in shares)				375,000
Cost of Goods Sold [Member]
Employee Service Share-based Compensation, Aggregate Disclosures [Abstract]
Allocated share-based compensation expense		$ 2,691	$ 5,800	$ 8,479	19,800
Research and Development Expense [Member]
Employee Service Share-based Compensation, Aggregate Disclosures [Abstract]
Allocated share-based compensation expense		56,251	3,600	172,346	19,000
Selling, General and Administrative Expenses [Member]
Employee Service Share-based Compensation, Aggregate Disclosures [Abstract]
Allocated share-based compensation expense		$ 447,646	$ 65,359	$ 1,050,141	$ 260,244

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES, Part 3 (Details) - USD ($)	3 Months Ended						6 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Jun. 30, 2019	Jun. 30, 2018	Sep. 30, 2019	Sep. 30, 2018	Dec. 31, 2018	Dec. 31, 2017
Geographic Areas, Revenues from External Customers [Abstract]
Sales	$ 9,720,939	$ 9,888,136	$ 8,542,265	$ 9,825,125	$ 8,960,782	$ 8,024,945	$ 18,430,401	$ 16,985,727	$ 27,613,291	$ 26,810,852	$ 34,581,440	$ 25,208,951
Geographic Areas, Long-Lived Assets [Abstract]
Long-lived assets	5,245,794								5,245,794		2,873,920
Cash and Cash Equivalents [Abstract]
Cash and cash equivalents	21,867,892								21,867,892		12,524,551
Summary of accounts payable and accrued liabilities [Abstract]
Accounts payable - suppliers	2,975,913								2,975,913		3,622,765
Accrued commissions and royalties	819,405								819,405		867,344
Accrued payroll	320,266								320,266		48,867
Accrued vacation	659,358								659,358		264,789
Accrued bonuses	497,190								497,190		494,318
Accrued expenses - other	173,824								173,824		590,598
Total	5,445,956								5,445,956		5,888,681
Net Product Sales [Member]
Geographic Areas, Revenues from External Customers [Abstract]
Sales	8,510,629	$ 8,785,041	$ 6,624,285	8,304,370	$ 7,098,317	$ 6,706,040	$ 15,409,326	$ 13,804,357	23,381,906	22,108,727	27,913,209	$ 20,515,826
Level 2 [Member]
Cash and Cash Equivalents [Abstract]
Fair value of total debt	20,000,000								20,000,000		200,000
Carrying value	17,500,000								17,500,000
Africa [Member]
Geographic Areas, Revenues from External Customers [Abstract]
Sales	1,250,063			3,193,098					6,009,103	7,156,822
Africa [Member] \| Net Product Sales [Member]
Geographic Areas, Revenues from External Customers [Abstract]
Sales	1,250,063			3,193,098					6,009,103	7,156,822
Asia [Member]
Geographic Areas, Revenues from External Customers [Abstract]
Sales	505,379			216,527					746,025	1,212,839
Geographic Areas, Long-Lived Assets [Abstract]
Long-lived assets	419,719								419,719		466,185
Asia [Member] \| Net Product Sales [Member]
Geographic Areas, Revenues from External Customers [Abstract]
Sales	505,379			216,527					746,025	1,212,839
Europe & Middle East [Member]
Geographic Areas, Revenues from External Customers [Abstract]
Sales	1,629,965			1,666,066					4,880,744	3,831,580
Geographic Areas, Long-Lived Assets [Abstract]
Long-lived assets	157,257								157,257		123,752
Europe & Middle East [Member] \| Net Product Sales [Member]
Geographic Areas, Revenues from External Customers [Abstract]
Sales	1,027,147			728,073					2,946,813	1,773,872
Latin America [Member]
Geographic Areas, Revenues from External Customers [Abstract]
Sales	4,296,903			3,404,683					9,981,874	9,743,764
Latin America [Member] \| Net Product Sales [Member]
Geographic Areas, Revenues from External Customers [Abstract]
Sales	4,296,904			3,404,683					9,981,874	9,743,764
United States [Member]
Geographic Areas, Revenues from External Customers [Abstract]
Sales	2,038,629			1,344,811					5,995,545	4,865,847
Geographic Areas, Long-Lived Assets [Abstract]
Long-lived assets	4,668,818								4,668,818		2,283,983
United States [Member] \| Net Product Sales [Member]
Geographic Areas, Revenues from External Customers [Abstract]
Sales	1,431,136			$ 761,989					3,698,091	$ 2,221,430
Money Market Funds [Member] \| Level 1 [Member]
Cash and Cash Equivalents [Abstract]
Cash and cash equivalents	$ 20,500,000								$ 20,500,000		$ 4,700,000

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES, Part 4 (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018	Dec. 31, 2018
Goodwill [Abstract]
Goodwill impairment loss			$ 0	$ 0
Goodwill [Roll Forward]
Goodwill, Beginning balance			4,983,127
Chembio Diagnostics GmbH measurement period adjustment			(145,760)
Changes in foreign currency exchange rate			(155,856)
Goodwill, Ending balance	$ 4,681,511		4,681,511
Intangible assets [Abstract]
Net Book Value	3,508,594		3,508,594		$ 3,884,831
Amortization Expense [Abstract]
2019	499,871		499,871
2020	499,871		499,871
2021	499,871		499,871
2022	499,871		499,871
2023	499,871		499,871
Thereafter	$ 1,381,699		$ 1,381,699
Taxes [Abstract]
Effective tax rate	0.50%	0.00%	3.90%	0.00%
Intellectual Property [Member]
Intangible assets [Abstract]
Weighted Average Useful Life			10 years
Developed Technology [Member]
Intangible assets [Abstract]
Weighted Average Useful Life			7 years
Customer Contracts / Relationships [Member]
Intangible assets [Abstract]
Weighted Average Useful Life			10 years
Trade Name [Member]
Intangible assets [Abstract]
Weighted Average Useful Life			11 years
CDM [Member]
Amortization Expense [Abstract]
Amortization expense	$ 378,691	$ 134,208	$ 378,691	$ 134,208
OpTricon and CDM [Member]
Intangible assets [Abstract]
Cost	4,219,889		4,219,889		4,230,124
Accumulated Amortization	711,295		711,295		345,293
Net Book Value	3,508,594		$ 3,508,594		3,884,831
OpTricon and CDM [Member] \| Intellectual Property [Member]
Intangible assets [Abstract]
Weighted Average Useful Life			6 years
Cost	1,203,121		$ 1,203,121		1,089,688
Accumulated Amortization	258,045		258,045		173,633
Net Book Value	945,076		$ 945,076		916,055
OpTricon and CDM [Member] \| Developed Technology [Member]
Intangible assets [Abstract]
Weighted Average Useful Life			6 years
Cost	1,816,190		$ 1,816,190		1,910,315
Accumulated Amortization	194,592		194,592		0
Net Book Value	1,621,598		$ 1,621,598		1,910,315
OpTricon and CDM [Member] \| Customer Contracts / Relationships [Member]
Intangible assets [Abstract]
Weighted Average Useful Life			8 years
Cost	1,093,521		$ 1,093,521		1,121,600
Accumulated Amortization	231,894		231,894		151,929
Net Book Value	861,627		$ 861,627		969,671
OpTricon and CDM [Member] \| Trade Name [Member]
Intangible assets [Abstract]
Weighted Average Useful Life			8 years
Cost	107,057		$ 107,057		108,521
Accumulated Amortization	26,764		26,764		19,731
Net Book Value	$ 80,293		$ 80,293		$ 88,790

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES, Part 5 (Details) - USD ($)	3 Months Ended						6 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Jun. 30, 2019	Jun. 30, 2018	Sep. 30, 2019	Sep. 30, 2018	Dec. 31, 2018	Dec. 31, 2017
REVENUES:
Total revenues	$ 9,720,939	$ 9,888,136	$ 8,542,265	$ 9,825,125	$ 8,960,782	$ 8,024,945	$ 18,430,401	$ 16,985,727	$ 27,613,291	$ 26,810,852	$ 34,581,440	$ 25,208,951
COSTS AND EXPENSES:
Cost of product sales	6,649,114	6,989,975	5,011,636	7,223,081	6,175,884	4,425,592	12,001,611	10,601,476	18,112,676	17,824,557	22,599,432	14,114,681
Total Costs and Expenses	13,328,641	13,187,937	11,637,951	12,154,962	10,714,512	8,679,263	24,825,888	19,393,775	37,616,480	31,548,736	42,564,108	31,691,501
CASH FLOWS FROM OPERATING ACTIVITIES:
Cash received from customers and grants			8,110,466			6,347,198	18,165,872	12,795,497	29,423,872	21,812,928	29,804,273	26,164,823
Cash paid to suppliers and employees			(12,590,425)			(8,666,444)	(24,959,732)	(17,900,495)	(35,185,776)	(29,386,421)	(41,624,299)	(31,221,823)
Net Product Sales [Member]
REVENUES:
Total revenues	$ 8,510,629	8,785,041	6,624,285	8,304,370	7,098,317	6,706,040	15,409,326	13,804,357	$ 23,381,906	22,108,727	27,913,209	20,515,826
ASU 2014-09 [Member] \| As Filed [Member]
REVENUES:
Total revenues		9,591,386	8,300,966	9,376,793	8,720,326	7,717,132	17,892,352	16,437,458		25,814,251	33,409,251	24,015,427
COSTS AND EXPENSES:
Cost of product sales		6,693,225	4,770,337	6,774,749	5,935,428	4,117,779	11,463,562	10,053,207		16,827,956	21,427,243	12,921,157
Total Costs and Expenses		12,891,187	11,396,652	11,706,630	10,474,056	8,371,450	24,287,839	18,845,506		30,552,135	41,391,919	30,497,977
CASH FLOWS FROM OPERATING ACTIVITIES:
Cash received from customers and grants			7,869,167			6,039,385	17,627,823	12,247,228		20,816,327	28,632,084	24,971,299
Cash paid to suppliers and employees			(12,349,126)			(8,358,631)	(24,421,683)	(17,352,226)		(28,389,820)	(40,452,110)	(30,028,299)
ASU 2014-09 [Member] \| As Filed [Member] \| Net Product Sales [Member]
REVENUES:
Total revenues		8,488,291	6,382,986	7,856,038	6,857,861	6,398,227	14,871,277	13,256,088		21,112,126	26,741,020	19,322,302
ASU 2014-09 [Member] \| Adjustment [Member]
REVENUES:
Total revenues		296,750	241,299	448,332	240,456	307,813	538,049	548,269		996,601	1,172,189	1,193,524
COSTS AND EXPENSES:
Cost of product sales		296,750	241,299	448,332	240,456	307,813	538,049	548,269		996,601	1,172,189	1,193,524
Total Costs and Expenses		296,750	241,299	448,332	240,456	307,813	538,049	548,269		996,601	1,172,189	1,193,524
CASH FLOWS FROM OPERATING ACTIVITIES:
Cash received from customers and grants			241,299			307,813	538,049	548,269		996,601	1,172,189	1,193,524
Cash paid to suppliers and employees			(241,299)			(307,813)	(538,049)	(548,269)		(996,601)	(1,172,189)	(1,193,524)
ASU 2014-09 [Member] \| Adjustment [Member] \| Net Product Sales [Member]
REVENUES:
Total revenues		$ 296,750	$ 241,299	$ 448,332	$ 240,456	$ 307,813	$ 538,049	$ 548,269		$ 996,601	$ 1,172,189	$ 1,193,524

STOCKHOLDERS' EQUITY (Details) - USD ($)		3 Months Ended	9 Months Ended
STOCKHOLDERS' EQUITY (Details) - USD ($)	Feb. 13, 2018	Mar. 31, 2018	Sep. 30, 2019	Sep. 30, 2018
Common Stock [Abstract]
Number of stock options exercised (in shares)			46,875	114,947
Common stock exercised on cashless basis (in shares)			24,075	71,290
Underwritten public offering (in shares)	1,783,760
Public offering price per share (in dollars per share)	$ 6.75		$ 5.40
Gross proceeds from public offering	$ 12,000,000	$ 10,934,352
Net proceeds after underwriting discounts and other offering expenses	$ 10,900,000		$ 0	$ 10,934,352

COMMITMENTS, CONTINGENCIES, AND CONCENTRATIONS (Details)

3 Months Ended

6 Months Ended

9 Months Ended

12 Months Ended

Sep. 30, 2019

USD ($)

KeyEmployee

Jun. 30, 2019

USD ($)

Mar. 31, 2019

USD ($)

Sep. 30, 2018

USD ($)

Jun. 30, 2018

USD ($)

Mar. 31, 2018

USD ($)

Jun. 30, 2019

USD ($)

Jun. 30, 2018

USD ($)

Sep. 30, 2019

USD ($)

KeyEmployee

Lease

Sep. 30, 2018

USD ($)

Dec. 31, 2018

USD ($)

Dec. 31, 2017

USD ($)

Sep. 03, 2019

USD ($)

Concentrations [Abstract]

Sales

$ 9,720,939

$ 9,888,136

$ 8,542,265

$ 9,825,125

$ 8,960,782

$ 8,024,945

$ 18,430,401

$ 16,985,727

$ 27,613,291

$ 26,810,852

$ 34,581,440

$ 25,208,951

Accounts Receivable

$ 5,377,985

7,373,971

Employment Contracts [Abstract]

Number of key employees with whom Company has employment contracts | KeyEmployee

Aggregate annual salaries of employment contracts

$ 820,000

Contract one, expiration date

Mar. 31, 2020

Contract two, expiration date

Dec. 31, 2021

Future minimum salary commitments [Abstract]

2019

$ 205,000

2020

478,800

2021

365,000

$ 365,000

Pension Plan [Abstract]

Percentage of employer's matching contribution

40.00%

$ 74,600

71,900

Leases [Abstract]

Number of leases entered | Lease

Number of subleases entered | Lease

Components of Lease Expense [Abstract]

Operating lease expense

425,757

$ 1,108,016

Finance lease cost [Abstract]

Amortization of right-of-use assets

11,686

Interest on lease liabilities

4,033

Total finance lease expense

15,719

Cash paid for amounts included in the measurement of lease liabilities [Abstract]

Operating cash flows for operating leases

158,050

474,150

Operating cash flows for finance leases

4,033

Financing cash flows for finance leases

9,851

Right-of-use assets obtained in exchange for lease obligations [Abstract]

Operating leases

6,697,896

Finance leases

222,036

Operating Leases [Abstract]

Operating lease right-of-use assets

6,697,896

Current portion of operating lease liability

255,030

Operating lease liabilities

6,706,918

Total operating lease liabilities

6,961,948

Finance Leases [Abstract]

Finance lease right of use asset

233,722

Accumulated depreciation

(11,686)

Finance lease right of use asset, net

222,036

Current portion of finance lease liability

41,169

Finance lease liability

182,702

Total finance lease liability

$ 223,871

Weighted Average Remaining Lease Term [Abstract]

Operating leases

9 years 10 months 24 days

Finance leases

4 years 9 months 18 days

Weighted Average Discount Rate [Abstract]

Operating leases

8.51%

Finance leases

7.00%

Maturities of Operating Lease Liabilities [Abstract]

$ 158,050

813,443

998,071

1,026,044

1,011,085

6,792,762

10,799,455

Less: imputed interest

3,837,507

Total

6,961,948

Maturities of Finance Lease Liabilities [Abstract]

13,884

55,536

55,536

55,536

55,536

27,767

263,795

Less: imputed interest

39,924

Total finance lease liability

223,871

Minimum Lease Payments under Non-cancellable Operating Leases [Abstract]

384,308

88,576

472,884

Senior Secured Term Loan Credit Facility [Member]

Leases [Abstract]

Debt instrument, face amount

$ 20,000,000

Customer Concentration Risk [Member] | Customer 1 [Member]

Concentrations [Abstract]

Accounts Receivable

2,209,986

3,499,340

Customer Concentration Risk [Member] | Customer 2 [Member]

Concentrations [Abstract]

Accounts Receivable

189,283

1,033,824

Supplier Concentration Risk [Member] | Vendor 1 [Member]

Concentrations [Abstract]

Accounts Payable

^[1]

Maximum [Member]

Pension Plan [Abstract]

Employee contribution subject to employer matching contribution

5.00%

Employer matching contribution

2.00%

Sales [Member] | Customer Concentration Risk [Member] | Customer 1 [Member]

Concentrations [Abstract]

Sales

$ 3,966,142

$ 3,256,390

$ 10,012,644

$ 9,241,445

Concentration risk, percentage

46.60%

39.00%

42.80%

42.00%

Sales [Member] | Customer Concentration Risk [Member] | Customer 2 [Member]

Concentrations [Abstract]

Sales

$ 0

$ 1,852,186

$ 4,378,773

$ 3,312,816

Concentration risk, percentage

0.00%

22.00%

18.70%

15.00%

Purchases [Member] | Supplier Concentration Risk [Member] | Vendor 1 [Member]

Concentrations [Abstract]

Concentration risk, percentage

^[1]

22.00%

^[1]

17.00%

Purchases

^[1]

$ 508,646

^[1]

$ 1,372,521

[1]	In the table above, an asterisk (*) indicates that purchases from the vendor did not exceed 10% for the period indicated or that accounts payable by the vendor did not exceed 10% of total accounts payable at the date indicated.

LONG-TERM DEBT (Details) - Note Payable - Equipment Vendor [Member] - USD ($)	1 Months Ended	9 Months Ended
	Sep. 30, 2017	Sep. 30, 2019
Debt Instruments [Abstract]
Debt instrument, face amount	$ 660,000
Percentage of first payment of the term	30.00%
Percentage of second payment of the term	60.00%
Percentage of prepayment after delivery	10.00%
Percentage of first payment of the term by the vendor	15.00%
Percentage of second payment of the term by the vendor	40.00%
Percentage of payment after delivery by the vendor	10.00%
Annual interest rate	12.00%
Periodic payment debt instrument, principal and interest	$ 20,150
Term of debt instrument		24 months

LONG-TERM DEBT, Credit Agreement (Details) - Senior Secured Term Loan Credit Facility [Member] - USD ($)		9 Months Ended
	Sep. 03, 2019	Sep. 30, 2019
Credit Agreement [Abstract]
Debt instrument, face amount	$ 20,000,000
Lender's closing cost	550,000
Financing fee	$ 600,000
Percentage of gross proceeds considered as financing fee	3.00%
Interest rate	8.75%
Increase in interest rate in event of default	4.00%
Principal installment payable	$ 300,000
Debt instrument maturity date		Sep. 03, 2023
Outstanding loan balance, net		$ 17,500,000
September 4, 2019 to September 3 ,2020 [Member]
Credit Agreement [Abstract]
Percentage of prepaid principal as premium	10.00%
September 4, 2020 to September 3 ,2021 [Member]
Credit Agreement [Abstract]
Percentage of prepaid principal as premium	8.00%
September 4, 2021 to September 3 ,2022 [Member]
Credit Agreement [Abstract]
Percentage of prepaid principal as premium	4.00%
LIBOR [Member]
Credit Agreement [Abstract]
Term of variable rate		1 month
Basis spread on variable rate	2.50%

WARRANT (Details) $ / shares in Units, $ in Millions	9 Months Ended
WARRANT (Details) $ / shares in Units, $ in Millions	Sep. 30, 2019 USD ($) $ / shares shares	Sep. 03, 2019 shares	Feb. 13, 2018 $ / shares
WARRANT [Abstract]
Warrant term	7 years
Warrants to purchase of common stock (in shares) \| shares		550,000
Estimated Fair Value of Warrant Assumptions [Abstract]
Stock price on issuance date (in dollars per share) \| $ / shares	$ 5.40		$ 6.75
Strike Price (in dollars per share) \| $ / shares	$ 5.22
Expected life	7 years
Fair value of warrants \| $	$ 1.4
Fair value of warrants (in dollars per share) \| $ / shares	$ 2.49
Warrants outstanding \| $	$ 1.2
Number of warrants exercised (in shares) \| shares	0
Number of warrants expired (in shares) \| shares	0
Risk-Free Interest Rate [Member]
Estimated Fair Value of Warrant Assumptions [Abstract]
Measurement input	0.0145
Volatility [Member]
Estimated Fair Value of Warrant Assumptions [Abstract]
Measurement input	0.4365

SUBSEQUENT EVENTS (Details) - Subsequent Event [Member] - Orangelife [Member]	Nov. 07, 2019 USD ($)
Acquisition [Abstract]
Payment of stock for acquisition	$ 850,000
Cash payment for acquisition	150,000
Maximum [Member]
Acquisition [Abstract]
Additional stock payment for acquisition based on certain milestones	$ 2,750,000